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Dengue virus (DENV), belonging to the Flaviviridae family and Flavivirus genus, is an 
arthropod-borne virus with four serotypes. Causing 390 million human infections 
annually, DENV infection can lead to life-threatening diseases such as dengue 
hemorrhagic fever or dengue shock syndrome, resulting in 200,000 deaths a year. This 
has been further exacerbated by the lack of DENV human vaccines and antivirals. 
DENV NS5 RNA-dependent RNA polymerase (RdRp), a viral-specific and highly 
conserved protein, is a promising drug target. In this study, DENV2 NS5 protein 
synthesized using the eukaryotic wheat germ cell-free protein synthesis system will be 
presented as an alternative to other present protein synthesis methods that balances cost, 
efficiency and physiological relevance. The recombinant NS5 proteins were then 
successfully applied in the development of a fluorescence-based in vitro NS5 RdRp 
assay. 
Against a background of failed clinical trials due to safety and pharmacokinetic 
concerns, an emerging importance has been placed on drug repositioning to develop 
novel uses for existing drugs. Hence, libraries of FDA-approved drugs and natural 
compounds, highly regarded as safer alternatives compared to experimental synthetic 
compounds, were screened. Compared to other similar studies, this study achieved a 
significantly higher hit rate of 1.2% using a conservative cut-off criterion, suggesting 
that the choice to screen these safer (i.e. less cytotoxic) drugs and compounds could be a 
more efficient way to identify RdRp inhibitors and could expedite the clinical trial 
process. 
Eight drugs/compounds were shortlisted by the primary screen, and their anti-DENV 
potential was further evaluated in a cell-based DENV infection system by exploring 
their cytotoxicity and capacity to reduce viral titers. Of these, 62.5% demonstrated anti-
DENV activity in cultured cells. Of these, kusunoki, a polyphenol-enriched extract rich 
in oligomeric proanthocyanidins derived from the bark of the Japanese cinnamon tree, 
reflected the highest SI, and was chosen for further downstream validation experiments. 
The antiviral effect of kusunoki is demonstrated to be reproducible in a cell-type and 
assay-independent manner. In addition, its broad-spectrum inhibition against all four 
DENV serotypes is shown. Insights into the mechanistic action of kusunoki suggest that 
in addition to being a RdRp inhibitor, it may also further inhibit DENV by preventing 
viral attachment to host cells prior to entry. Kusunoki therefore holds great potential as 
an anti-DENV compound for further development into an antiviral drug. 
 ix 
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Chapter 1. INTRODUCTION 
1.1  Dengue 
Dengue is a disease caused by dengue virus (DENV) infections and transmitted by 
mosquitoes. Tropical and sub-tropical regions around the world are among the most 
afflicted by the burden of this disease.  
The World Health Organization (WHO) ranks dengue as one of the most important 
infectious diseases in the world, with serious implications on international public health 
(Guzman and Kouri, 2002). Despite global efforts to curb dengue transmissions, both 
geographical disease distribution and transmission rates have been on the rise (Farrar et 
al., 2007) (Figure 1.1).
 




1.1.1  Burden of disease 
Dengue incidence has brought a significant economic and disease burden. A substantial 
economic burden in endemic countries, the disease has cost countries US$950 million 
and US$2.1 billion annually in Southeast Asia and the Americas respectively. As the 
study in the Americas have not included components such as cost for vector control, the 
economic consequences of dengue remains significantly underestimated (Shepard et al., 
2011; Shepard et al., 2013). 
The incidence of dengue has also increased globally in recent decades. Presently, 
estimates by the WHO places well over 2.5 billion people (approximately 40% of the 
world's population) at risk of dengue, with as many as 50 – 100 million dengue 
infections worldwide every year (Special Programme for Research and Training in 
Tropical Diseases. and World Health Organization., 2009). However, in a recent report 
by Bhatt and colleagues, the global dengue burden was demonstrated to be more than 
three times that of WHO’s estimates, with a staggering 390 million infection cases 
occurring annually (Bhatt et al., 2013).  
Up to the 1970s, only nine countries had experienced critical dengue epidemics. In 
dramatic contrast, dengue is now endemic in more than 100 countries in Africa, the 
Americas, the Eastern Mediterranean, South-east Asia and the Western Pacific 
(Chaturvedi and Shrivastava, 2004).  
The evident increase in DENV epidemic activity has been attributed to several factors. 
Firstly, the unprecedented population growth in developing areas coupled to the lack of 
reliable water systems have exacerbated this condition by the need to collect and store 
water, increasing mosquito breeding potential. The advent of modern day transportation 
has also increased movement of viruses in infected humans, contributing to the 
geographic spread of the virus. Moreover, ineffective control of its mosquito vector, 
Aedes aegypti, can also be ascribed for the continued viral spread and maintenance of 
the virus reservoir and (Mackenzie et al., 2004). Lastly, being the only known arbovirus 
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to have fully adapted to humans, DENV are no longer dependent on an enzootic cycle 
for maintenance (Gubler, 2002). 
1.1.2  Dengue virus 
The Flavivirus genus, belonging to the family Flaviviridae, contains 73 viruses, and 
many of which are arthropod-borne, or arboviruses, a term that depicts the necessity of a 
blood-sucking arthropod to complete their life cycle. Of these, pathogenic flaviviruses 
include the DENV, West Nile virus (WNV), yellow fever virus (YFV), Japanese 
encephalitis virus (JEV) and tick-borne encephalitis virus (TBEV) that pose major 
public health threats worldwide. These have been known to be causative agents of 
emerging infectious diseases, a phenomenon epitomized by the escalating prevalence of 
DENV, especially in the tropical and subtropical regions of the world (Malet et al., 
2008). 
1.1.3  Dengue infection pathogenesis 
Four related but antigenically distinct DENV (DENV serotypes 1 – 4 [DENV-1 to -4]) 
infect approximately 390 million people annually (Bhatt et al., 2013). In most cases, 
after an incubation period of 4 – 7 days, clinical manifestations of DENV infection vary, 
and risk factors that determine severity of the disease include age, ethnicity  and existing 
chronic diseases (Bravo et al., 1987; Guzman et al., 2002; Guzman et al., 2000). 
1.1.3.1  Dengue fever 
Generally, DENV infections are asymptomatic or result in dengue fever (DF), a mild, 
undifferentiated and self-limiting disease associated with fever and malaise. Other 
symptoms may include a severe headache with retro-orbital pain, severe joint and 
muscle aches, nausea and vomiting and body rash (Simmons et al., 2012). Less than 
10% of symptomatic dengue cases are reported, and a prospective cohort study of 
elementary school children in Thailand revealed that an average of approximately 53% 
of dengue cases were asymptomatic over a three-year period from 1998 to 2000 (Endy 
et al., 2002). The likelihood of symptomatic infections rises upon secondary infections, 
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as well as a longer time interval between primary and secondary infections (Anderson et 
al., 2013; Seet et al., 2005). 
1.1.3.2  Dengue hemorrhagic fever and dengue shock syndrome 
Of the total number of DENV infections, a small but significant subset of cases totaling 
to about 500,000 annually develop to life threatening dengue hemorrhagic fever (DHF) 
and dengue shock syndrome (DSS). Also known as severe dengue, clinical symptoms 
often resemble those of classical dengue fever during its early stages.  
However, in DHF/DSS cases, a persistent high fever is then further complicated by 
acute conditions characterized by plasma leakage and abnormal haemostasis. Evidence 
supporting the former includes a swift rise in haemotocrit, pleural effusion and ascites, 
hypoproteinaemia and reduced plasma volume (Bhamarapravati et al., 1967; 
Nimmannitya, 2009). Atypical haemostasis is associated with vascular changes such as 
capillary fragility changes, thrombocytopenia, coagulopathy and depression of bone 
marrow elements (Bokisch et al., 1973; Deen et al., 2006; Srichaikul and Nimmannitya, 
2000). Severe dengue leads to 200,000 deaths annually, a condition which is 
exacerbated by the lack of intravenous fluid resuscitation facilities in some regions 
(Julander et al., 2011; Ngo et al., 2001). DSS occurs largely in childhood cases, and has 
been hypothesized to be due to increased microvascular permeability in children who 
are still developing compared to adults (Gamble et al., 2000). 
The pathogenesis behind the development of DHF/DSS remains elusive. A primary 
infection with any of the four DENV serotypes is known to result in a lifelong immunity 
to that particular serotype. In addition, this primary infection also provides a short-lived 
immunity to the other serotypes that lasts a few months (Gubler, 1998). While the 
primary infection is most often asymptomatic, subsequent infections by any of the other 




One of the leading hypotheses for this occurrence is the antibody-dependent 
enhancement (ADE) effect (Halstead, 1970). Halstead and his colleagues were one of 
the first proponents of this hypothesis after early studies in the 1950s that suggested that 
DHF/DSS occurs 15–80 times more commonly in secondary infections than in primary 
ones. Furthermore, a striking 99% of DHF cases reveal heterotypic antibodies to the 
dengue serotype causing the DHF (Halstead, 1982). 
In brief, a primary infection causes the development of homotypic neutralizing 
antibodies against the DENV serotype responsible. Concurrently, heterotypic antibodies 
against other serotypes are also generated. This confers the host the lifelong immunity 
against this serotype and transient cross-immunity to other serotypes (Sabin, 1952). This 
is explained by the observation that specific neutralizing IgG antibodies against the 
infecting DENV lasts decades, while heterotypic IgG antibodies decline rapidly over 
time (Halstead, 1974; Vaughn et al., 2008). This discrepancy could be due to the 
preferential survival of long-lived memory B cells producing homotypic antibodies 
(Guzman et al., 2007).  
Besides these two categories of antibodies, it is also possible for non-neutralizing 
heterotypic antibodies to be produced. This subset of antibodies enhances DENV entry 
into host cells upon onset of a secondary infection, leading to augmented infectivity. 
Interestingly, studies have revealed that a primary infection with DENV-1 or DENV-3 
often resulted led to a more severe disease outcome compared to if DENV-2 or DENV-
4 (Vaughn et al., 1997). 
1.2  Characteristics of DENV and DENV genome 
DENV are small enveloped viruses. Although widely accepted that two states of 
maturation exist (mature and immature virions), there have been increasing evidence of 
intermediate forms as well (Allison et al., 1999a; Rey et al., 1995).  
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A mature DENV virion is approximately 50 nm in diameter with a icosahedral capsid 
which contains a single-stranded, positive-sense RNA genome (Kuhn et al., 2002; Singh 
and Ruzek, 2013) that is organized with a type-I 5’ cap analog (m7GpppA) attached to 
the 5’-untranslated region (UTR), a single large open reading frame and the 3’UTR 
(Tomlinson et al., 2009). The DENV RNA genome (approximately 11 kb in length) 
encodes for 10 proteins (Figure 1.2), of which three are structural (capsid [C], pre-
membrane [prM] and envelope [E]) and the remaining seven are non-structural (NS1, 
NS2A, NS2B, NS3, NS4A, NS4B and NS5) proteins.  
In general, the structural and non-structural proteins function at distinct steps in virus 
replication: structural proteins for virion formation and non-structural proteins for RNA 
replication, respectively (Kummerer and Rice, 2002). Supporting this, the simultaneous 
expression of DENV C, E and prM proteins is ample for the secretion of virus-like 
particles that recapitulate the envelope structure and fusogenic ability of the mature 
virion (Tan et al., 2007). Also, DENV-derived subgenomic RNA replicons deficient in 
structural proteins retain replicative capabilities in cells, whereas they can be packaged 
into virions and released by trans expression of the structural proteins (Zou et al., 2011). 
While this still largely holds true, this view has been challenged with proteins that seem 
to have dual functions overarching both categories, effectively blurring the boundary 
between the two exclusive categories.  
 
Figure 1.2 | The DENV genome (Adapted from Yap et al., 2007) 
 7 
 
1.2.1  Structural proteins 
DENV particles are made up of a host-derived lipid bilayer embedded with 
heterodimers of the E glycoprotein and the M protein which interact at their C-terminal 
ends (Allison et al., 1999b; Kuhn et al., 2002). Within the virion core, a nucleocapsid of 
about 40Å in diameter that is assembled of multiple C proteins encapsulates its RNA 
genome. 
1.2.1.1  Capsid (C) protein 
The C protein is a relatively small protein of about 9 kDa. Multiple C proteins assemble 
to form the viral nucleocapsid that is within the virion core. 
A high proportion of amino acids found in the C protein are basic in nature. This 
suggests a likely function of the C protein in packaging negatively charged viral RNA, 
possibly through electrostatic interactions (Ma et al., 2004; Rawlinson et al., 2006). An 
internal signal sequence located at the C-terminal end of the protein enables the 
attachment of C protein to the endoplasmic reticulum (ER) membrane, initiating the site 
of nucleocapsid assembly (Nowak et al., 1989). 
The C protein has also been implicated to have a role in viral RNA replication. While 
some studies have concurred that the first 20 amino acids of the C protein are important 
for efficient viral replication, others have also demonstrated that the sequences slightly 
upstream of the C protein gene are involved in cyclization with the 3’ UTR region to 
enable full-length genome synthesis (Ditursi et al., 2006; Wu et al., 2005). 
1.2.1.2  Pre-membrane (prM) and membrane (M) proteins  
The glycosylated prM protein is approximately 18 kDa and can be found in immature 
virions located intracellularly. It then undergoes changes to form the M protein of about 
7 kDa and is located in mature virions.  
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The function of E protein is highly dependent on prM protein as co-expression of the 
two has been shown to be required for correct folding, maturation and proper assembly 
of E protein (Wu et al., 2005). The primary function of prM is to prevent the premature 
rearrangement of the E protein under mildly acidic conditions of the trans-Golgi 
network before virion release (Botting and Kuhn, 2012). By forming a heterodimer with 
E protein, the prM/E complex effectively conceals the fusion peptide situated on the E 
protein, thereby preventing premature fusion during the assembly process prior to 
release(Zhang et al., 2003). Host protease furin has been reported to cleave prM to yield 
fusion-competent mature virions with M proteins (Zybert et al., 2008). 
More recently, the prM protein has also been shown to play a role during virus entry. The 
interaction of prM to claudin-1, a tight junction membrane protein, has been suggested to 
facilitate internalization of DENV into cells (Zhou et al., 2007).  
1.2.1.3  Envelope (E) protein 
The E protein is approximately 55 kDa and is a major glycoprotein found on the surface 
of the virion. It has been found to be glycosylated in most flaviviruses (Winkler et al., 
1987). It is vital for cell receptor attachment and consequently, subsequent infections. 
Some of these receptors include GRP78 (glucose regulating protein 78), Hsp70, Hsp90 
(heat shock protein 70/90), CD14, laminin receptor, mannose receptor and DC-SIGN 
(Chen et al., 1999; Jindadamrongwech et al., 2004; Miller et al., 2008; Reyes-Del Valle 
et al., 2005; Tassaneetrithep et al., 2003; Thepparit and Smith, 2004). Following which, 
it then facilitates fusion of the virus to host cell membrane within infected cells. As it 
also bears neutralization epitopes, it is often the target of antibodies (Mukhopadhyay et 
al., 2005). 
On a mature virion, E proteins are present as a homodimer with each subunit organized 
in a head-to-tail manner (Kuhn et al., 2002; Rey et al., 1995). These are anchored in the 
viral membrane by a stem anchor region that extends from the end of the dimer (Allison 
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et al., 1999a). It is estimated that about 90 E proteins can be found on the virion surface 
(Kuhn et al., 2002). 
1.2.2  Non-structural (NS) proteins 
The seven NS proteins are components of the viral replication complexes (Mackenzie et 
al., 1998). However, in addition to their role in the replication of the RNA genome, they 
are also implicated in various other processes such as virion assembly and evasion of 
innate immune response (Elliott, 2011). 
1.2.2.1  NS1 protein 
NS1 protein is a 50 kDa glycoprotein that contributes to different stages of the viral life 
cycle (Gutsche et al., 2011; Mackenzie et al., 1996). Although not present in viral 
particles, it has been observed to accumulate in both in the supernatant and on plasma 
membranes during infection (Avirutnan et al., 2007). A portion of NS1 protein is 
retained intracellularly, and is understood to play a crucial role in viral RNA replication 
(Avirutnan et al., 2006; Lindenbach and Rice, 1997). NS1 protein is also secreted by 
DENV infected cells into the blood stream (Flamand et al., 1999).  
 
The amount of NS1 protein found circulating in human sera has been found to be higher 
in patients suffering from DHF compared to those with milder dengue fever (Wu et al., 
2005). Immune recognition of NS1 protein has been postulated to be a possible 
mechanism for vascular leakage, contributing to DHF (Avirutnan et al., 2006). 
 
Both membrane-associated and secreted forms of NS1 protein are also implicated in the 
immune response against DENV infection. This may be via the regulation of 
complement activation pathways through the creation of immune complexes or 
association with host proteins such as clusterin (Yap et al., 2007). 
1.2.2.2  NS2A protein 
  
NS2A protein is a hydrophobic protein of approximately 22kDa known to be associated 
with the membrane of the endoplasmic reticulum with five membrane-spanning 
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segments (Ditursi et al., 2006; Wu et al., 2005). Apart from the full length NS2A 
protein, another truncated form of NS2A protein, NS2Aα protein, has also been reported 
in virus infected cells. NS2Aα protein results from the C-terminal cleavage of 34 amino 
acids by viral NS2B-3 protease after K190 at the sequence QK↓T within NS2A protein 
(Wu et al., 2005). A multi-faceted protein, NS2A/NS2Aα protein has been recognized 
to have four main roles.  
 
Firstly, it is important for viral RNA synthesis as it has been observed to be part of the 
replication complex, together with double-stranded (ds) form of viral RNA, NS3 and 
NS5 proteins (Mackenzie et al., 1998). Secondly, it is also involved in viral assembly. In 
particular, amino acid residue Arg84 has been found to be critical for both RNA 
synthesis and viral assembly (Ditursi et al., 2006). This is also supported by the study by 
Kummerer and Rice which found that a lysine mutation (K190S) in NS2A blocked the 
production of both NS2Aα protein and infectious virus particles (Kummerer and Rice, 
2002). Thirdly, expression of NS2A alone is sufficient to subvert the host immune 
response by disruption of interferon α/β response such as through the blocking of 
dsRNA-activated protein kinase PKR (Munoz-Jordan et al., 2003; Niyomrattanakit et 
al., 2011). In addition, NS2A protein is also engaged in virus-induced membrane 
formation (Leung et al., 2008). 
1.2.2.3  NS2B protein 
 
NS2B protein is approximately 14 kDa and primarily functions as a cofactor for NS3 
protease (Falgout et al., 1991). Although DENV NS3 protein is shown to have NS2B-
independent protease activity for certain substrates (eg. N-benzoyl-L-arginine-p-
nitroanilide), its enzymatic activity was significantly increased with the NS2B cofactor 
(Zhou et al., 2007).  
 
In earlier studies, the minimal requirement of NS2B protein as a NS3 protease cofactor 
was found to be a 40-residue central hydrophilic region spanning from amino acid 
 11 
 
residue 54 to 93, a conserved region amongst flaviviruses (Ditursi et al., 2006). Deletion 
analysis in later reports then contributed to existing knowledge by revealing that this 
conserved portion was only sufficient for basal cofactor activity, as the optimal NS2B 
cofactor function was highly dependent on the hydrophobic flanking regions of the 
protein, presumably acting as an anchor of the protease complex to the ER membrane 
(Fryxell, 1980; Ng et al., 2007) 
 
1.2.2.4  NS3 protein 
 
NS3 protein, a multifunctional 618 amino acid long protein of about 70 kDa, is known 
to have demonstrated serine protease function, along with RNA helicase and nucleotide 
triphosphatase (NTPase) activities (Warrener et al., 1993; Wengler et al., 1991). 
Mutagenesis studies in the both the protease and helicase domains resulted in the 
abrogation of infectious virus particles, demonstrating the absolute requirement of these 
enzymes for viral replication (Lescar et al., 2008; Matusan et al., 2001). In addition, 
NS3 protein has also been implicated in viral assembly (Kummerer and Rice, 2002; 
Patkar and Kuhn, 2008).  
 
The protease domain is located in the N-terminal 186 amino acids of the NS3 protein 
(Lescar et al., 2008). It contains a characteristic canonical catalytic triad of His51, 
Asp75 and Ser135 that is well conserved both within the 4 serotypes of DENV as well 
as other flaviviruses (Chambers et al., 1990; Valle and Falgout, 1998). Together with its 
cofactor NS2B, the heterodimeric NS2B-NS3 protease complex (NS2B3) is essential for 
the viral replication cycle due to its ability to proteolytically process the precursor 
polyprotein (Chambers et al., 1990; Falgout et al., 1991). The NS2B3 serine protease is 
responsible for NS2A/NS2B, NS2B/NS3, NS3/NS4A and NS4B/NS5 junction 
cleavages (Brinkworth et al., 1999; Chambers et al., 1990; Falgout et al., 1991; 
Preugschat et al., 1990) as well as cleaving within C, NS3 and NS4A proteins (Arias et 




More recently, the NS2B3 protease complex was implicated with the inhibition of type I 
interferon (IFN) response by reducing the activity of IFN-β promoter. This has been 
shown to be achieved by the protease cleavage of human mediator of IRF3 activation 
(MITA), which in turn then prevents the phosphorylation needed for the activation of 
IRF3 (Rodriguez-Madoz et al., 2010; Yu et al., 2012). A similar phenomenon is also 
seen with hepatitis C virus (HCV) NS34A protease complex that proteolytically 
processes the IPS-1, interfering the signaling cascade that ends with the activation of 
IRF3 (Loo et al., 2006). 
 
The helicase/NTPase domain of NS3 lies in its C-terminal region and its enzymatic 
activities is ATP-driven. It is generally thought to hold apart the dsRNA intermediate 
that occurs during viral genome replication (Yap et al., 2007). It could also further 
enhance this important process by interfering with secondary structures formed by the 
single-stranded RNA template or oust any other factors that could potentially disrupt the 
replicative process (Lescar et al., 2008). Mutations in the helicase domain resulted in the 
abolished viral infectivity, demonstrating essentiality of this enzymatic activity in the 
viral replication cycle (Matusan et al., 2001). 
 
In addition, the third enzymatic domain of NS3 protein is the C-terminal RNA-5’-
triphosphatase (RTPase) domain. This has been proposed to be involved in RNA 
capping for the recognition by host translation machinery (Bartelma and Padmanabhan, 
2002). More recent studies have also suggested that NS3 NTPase and RTPase activities 
could possibly share a common active site (Benarroch et al., 2004). 
1.2.2.5  NS4A protein 
Comparatively less is known about the 16 kDa small hydrophobic integral membrane 
protein NS4A, which associates with membranes with 4 internal hydrophobic regions 
(Miller et al., 2007). The N-terminal region of NS4A protein is exposed in the 
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cytoplasm by cleavage from the NS2B3 protease complex. The C-terminal product of 
about 23 amino acid residues, on the other hand, has been suggested to act as a signal 
sequence that is crucial for the translocation of NS4B protein into the lumen of the ER. 
This signal sequence is called the 2K fragment and is then removed from the N-terminal 
region of NS4B protein by host signalase (Miller et al., 2007). This removal is in turn 
dependent on the prior cleavage at the NS4A/2K junction by NS2B3 protease (Lin et al., 
1993). 
In studies with Kunjin virus, the pre-cleaved full-length NS4A protein has been shown 
to induce intracellular membrane rearrangements, a process which could be essential in 
the formation of a unique scaffold to support the viral replication complex (Norman et 
al., 1983). The removal of the C-terminal 2K fragment led to a smaller degree of 
membrane rearrangement (Norman et al., 1983). 
Indeed, this observation was supported in a recent study by Miller et al., which showed 
that during DENV infection, NS4A protein was primarily localized in ER-derived 
cytoplasmic dot-like structures that contain dsRNA and other DENV proteins, further 
reinforcing the notion that NS4A protein as a constituent of the membrane-bound viral 
replication complex (Miller et al., 2007). The expression of N-terminal NS4A lacking 
the 2K fragment led to the induction of membrane alterations, as observed in Norman’s 
study, however, the expression of full-length NS4A could not. This highlights the 
importance of the proteolytic processing and removal of the 2K fragment in the 
induction of cytoplasmic membrane alterations for the formation of virus-induced 
structures to support the viral replication complex (Miller et al., 2007; Norman et al., 
1983). 
1.2.2.6  NS4B protein 
NS4B protein, like NS4A protein, is a small hydrophobic protein made up of 248 amino 
acids. NS4B proteins of the various DENV serotypes share approximately 82% 
similarity, while NS4B proteins of other flaviviruses such as WNV and HCV are only 
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35% similar and completely dissimilar to DENV NS4B protein respectively (Umareddy 
et al., 2006). Despite the vast differences in sequences, the general topology of NS4B 
protein of different flaviviruses comprising of numerous endoplasmic reticular and 
cytoplasmic domains divided by transmembrane regions bear great resemblance to each 
other, proposing a conserved function of NS4B protein in the viral replication cycle 
(Lundin et al., 2003; Miller et al., 2006). 
Both deletion of NS4B and mutations in its sequence are reported to inhibit replication 
of bovine viral diarrhea virus (BVDV) (Balint et al., 2005). The role of NS4B protein in 
viral replication has also been suggested by the observation that NS4B protein interacts 
with NS3 to enhance helicase activity and NS5 protein (Piccininni et al., 2002; Qu et al., 
2001; Umareddy et al., 2006), as well as a study reporting the NS4B-induced 
morphological changes in endoplasmic reticulum membrane (Egger et al., 2002). 
However, a conflicting account by Westaway and colleagues, who reported the inability 
to pull-down NS4B protein with dsRNA seemed to dispel the hypothesis of NS4B 
protein as a part of the viral replication complex (Westaway et al., 2003).  
In addition, NS4B protein has also been implicated to be engaged in the formation of a 
scaffold for the viral replication complex (Welsch et al., 2009), as well as its ability to 
subvert host immunity by the dampening of IFN-α/β response (Munoz-Jordan et al., 
2005). 
1.2.2.7  NS5 protein 
The multifunctional DENV NS5 protein is the largest DENV protein at 104 kDa. It is 
also the most conserved DENV protein, with NS5 proteins across the 4 DENV 
serotypes sharing almost 70% in amino acid sequence homology (Xu and Wang, 1991). 
The N-terminal region of NS5 protein has a S-adenosyl-methionine methyltransferase 
(SAM) domain, or simply known as a methyltransferase (MTase) domain. This domain 
is approximately 300 amino acids long and is known to facilitate the capping of viral 
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RNA and internal RNA methylation (Dong et al., 2012; Egloff et al., 2002). NS5 MTase 
has demonstrated methylase activity at both N7 position of guanine and 2’-OH position 
of ribose (Egloff et al., 2002). More recently, it has also been recently purported to have 
guanylyltransferase activity (Issur et al., 2009). These methylation events are essential 
for the capping of viral RNA, which in turn is vital for ribosomal recognition to 
facilitate host-mediated translation. 
Besides having MTase domain, two putative nuclear localization signals (NLSs), 
designated the βNLS and αβNLS, have also been uncovered in DENV NS5. The latter 
plays a more major role in nuclear transport facilitated by interaction with the cellular 
nuclear transport receptor -importin (Johansson et al., 2001). A high proportion NS5 
protein accumulates in the nuclei during DENV-2 infection, similar to that of NS5 
protein in YFV infection (Buckley et al., 1992). Although nuclear accumulation was 
thought to be directly correlated to efficient replication previously, a shift of paradigm 
has occurred with a study that uncoupled both processes through mutagenesis studies 
(Kumar et al., 2013).  
To date, the exact reason for NS5 protein nuclear accumulation during infection remains 
elusive. It is interesting to note, however, that this phenomenon is neither conserved 
amongst all 4 DENV serotypes nor other flaviviruses. NS5 protein of WNV, for 
example, does not demonstration nuclear localization during infection (Mackenzie et al., 
2007). These stark differences have been hypothesized to reflect the differences in 
strategies used by viruses to achieve efficient replication and could even correlate with 
pathogenesis in vivo (Kumar et al., 2013). Another possible consequence of NS5 protein 
nuclear accumulation is enhanced production of the immunomodulatory cytokine IL-8, 
the secretion of which seems to be impacted by the former (Medin et al., 2005; Pryor et 
al., 2007). 
NS5 protein also has a RNA-dependent RNA polymerase (RdRp) domain at its C-
terminus, which is characterized by the existence of the highly conserved motif C 
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(glycine, aspartate, aspartate) and similar to those found in RdRps of other RNA 
viruses. This domain is primarily responsible for the synthesis of viral RNA genome 
(Nomaguchi et al., 2003). The DENV RdRp is able to initiate RNA synthesis de novo 
(Ackermann and Padmanabhan, 2001). Mutagenesis studies involving the disruption of 
motif C have also been shown to abrogate the replication ability of flaviviruses 
(Khromykh et al., 1998), underscoring the significance of this enzyme to the viral life 
cycle. 
Besides these enzymatic activities, the role of NS5 protein in the evasion of innate 
immune response by binding to STAT2 and mediating its degradation is also well 
characterized (Ashour et al., 2009). More recently, UBR4, a 600 kDa member of the N-
recognin family was identified as an interacting partner of NS5 protein as data 
suggested that NS5 protein aided bridging between STAT2 and UBR4. The study also 
revealed that UBR4 promoted STAT2 degradation mediated by DENV infection, and 
was necessary for efficient viral replication in type-I IFN competent cells, thereby 
adding to existing knowledge by identifying UBR4 as a host protein exploited by 
DENV to inhibit IFN signaling via STAT2 degradation (Morrison et al., 2013). 
Another noteworthy interaction of NS5 protein is to NS3 protein. Interestingly, the 
region of NS5 protein binding to NS3 protein is thought to be the same region that binds 
to β-importin (Johansson et al., 2001). In a study by Yon and colleagues, the crosstalk 
between both NS3 and NS5 protein domains were demonstrated as NS5 protein 
stimulated the NTPase and RTPase activities of NS3 protein (Yon et al., 2005). 
1.3  DENV replication cycle 




Figure 1.3 | DENV replication cycle (Adapted from Stiasny and Heinz, 2006) 
1.3.1  Entry and uncoating 
DENV infects and replicates in a myriad of mammalian cells, including monocytes, 
macrophages, dendritic cells, endothelial cells, B and T leukocytes, heptocytes and 
kidney-derived cells (Alhoot et al., 2011). To kick-start its replication cycle, E/prM 
protein on the viral envelope attaches to a cell receptor such as GRP78 (glucose 
regulating protein 78), Hsp70, Hsp90 (heat shock protein 70/90), CD14, laminin 
receptor, mannose receptor and DC-SIGN (Chen et al., 1999; Jindadamrongwech et al., 
2004; Miller et al., 2008; Reyes-Del Valle et al., 2005; Tassaneetrithep et al., 2003; 
Thepparit and Smith, 2004). The DENV particle is then internalized into the cell 
cytoplasm by membrane fusion and enters the host cell by endocytosis. Following the 
acidification of endocytic vesicles, the exposed fusion loop causes the viral and cell 
membrane to be in close proximity, enabling the trimerization of E protein and thereby 
mediating virus and cell membrane fusion (Allison et al., 1995; Modis et al., 2003). The 
nucleocapsid enters the cytoplasm, uncoats, and releases the viral RNA genome 
(Tomlinson et al., 2009). 
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1.3.2  Translation and further processing 
After the single-stranded, positive-sense viral genomic RNA is released into the 
cytoplasm, the 5’UTR directs the RNA strand to host ribosomes for translation into a 
single long polyprotein. This is then co- and posttranslationally processed by a 
combination of both viral and host proteases (Figure 1.4).  
The NS2B3 serine protease is responsible for NS2A/NS2B, NS2B/NS3, NS3/NS4A and 
NS4B/NS5 junction cleavages (Brinkworth et al., 1999; Chambers et al., 1990; Falgout 
et al., 1991; Preugschat et al., 1990) as well as cleaving within C, NS3 and NS4A 
proteins(Arias et al., 1993; Lin et al., 1993; Teo and Wright, 1997). The cleavage of the 
remaining protein junctions C/prM, prM/E, E/NS1 and NS4A/NS4B are facilitated by 
host signal peptidases (Nowak et al., 1989; Speight et al., 1988), while prM protein is 
cleaved by furin to produce the mature M protein during virus maturation (Stadler et al., 
1997). 
 
Figure 1.4 | Schematic representation of DENV proteolytic processing (Adapted 
from Natarajan, 2010) 
1.3.3  RNA replication 
Viral RNA replication is catalyzed in a specialized structure known as the replication 
complex. Although the DENV replication complex is hypothesized to form when NS1, 
NS2A, NS3 and NS4A join NS5 in the vicinity of the 3’ stem loop after translation of 
viral RNA (Chambers, 2003), the main components of the replication complex are NS5  
and NS3. This structure is thought to be anchored to the trans-Golgi network membrane 
via the viral integral membrane protein, NS4A. 
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From the positive-sense RNA genome, a negative RNA strand is synthesized. This 
forms a double-stranded RNA called the Replication Form (RF). Using this as a 
template, the replication complex produces a Replicative Intermediate (RI), which is 
then further processed to form single stranded positive-sense RNA. The RF is then 
recycled continuously as a template for asymmetric and semi-conservative RNA 
synthesis (Chu and Westaway, 1985). 
1.3.4  Assembly and release 
Subsequent to RNA replication, C proteins interact with the positive-sense viral genome 
and are brought to the ER. The nucleocapsid is then enveloped with a lipid bilayer. 
Heterodimers of the E glycoprotein and the prM protein are then embedded on the 
nucleocapsid that form projections (Kuhn et al., 2002), facilitating the viral assembly 
process. The primary function of prM is to prevent the premature rearrangement of the 
E protein under mildly acidic conditions of the trans-Golgi network before virion 
release (Botting and Kuhn, 2012).  
Several of the DENV NS proteins like NS2A and NS3 (Liu et al., 2002) have also been 
reported to play a role in this process. For example, NS2A have been implicated in the 
biogenesis of virus-induced membranes, while NS3 has been postulated to play a role as 
a linker between structural proteins and RNA (Leung et al., 2008; Liu et al., 2002).  
Immature virions from the endoplasmic reticulum are then transported onward to the 
trans-Golgi network, where prM protein is cleaved by cellular furin to allow M/E 
rearrangement, resulting in virus maturation and release of the mature virion contained 
in vesicles through exocytosis (Li et al., 2008). 
1.4  Anti-dengue efforts 
DENV infection has become a growing global health concern by the sheer number of 
people estimated to be at risk of this infection and startling fatality rates annually. This 
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has also placed a heavy financial burden on health care systems around the world as 
many infected individuals seek treatment.  
To keep the disease at bay, governments in endemic regions worldwide have focused on 
mosquito vector control. These efforts may be divided into three main categories: 
Biological control (e.g. the introduction of larvivorous organisms such as fish into water 
containers and the release of transgenic vectors with the aim of reducing wild-type 
vectors  with those of a reduced capacity to reproduce and transmit disease), 
environmental management (e.g. covering and screening of water containers and 
reduction of human-vector contact by the use of screening doors and insecticide-treated 
nets), as well as chemical control (spraying of insecticides) (Erlanger et al., 2008; 
Simmons et al., 2012). The use of insecticides such as dichlorodiphenyltrichloroethane, 
malathion and pyrethroids, however, has been laden with challenges. These include 
environmental contamination, in particular that of aquatic ecosystems as pyrethroids are 
known to be toxic to aquatic life even at low levels (Friberg-Jensen et al., 2003). In 
addition, bioaccumulation of toxins and human toxicity, especially relating to the 
presence of insecticide in drinking water containers have also been of concern (Curtis 
and Lines, 2000). With evidence supporting the bioaccumulation of pyrethroids in 
mammalian tissue and possible maternal transfer of pyrethroids revealed by its presence 
in human breast milk (Alonso et al., 2012; Sereda et al., 2009), it is worrying that 
studies have also linked these same compounds to breast cancer (Go et al., 1999). Also, 
in a recent study by Luz et. al., it was reported that adult mosquito control was 8.2 times 
higher the cost of larval control and therefore the authors propagated the use of the 
latter. Another severe limitation of the effectiveness of chemical vector control was 
noted to be the short-term reduction in dengue burden of  merely 2 – 4 years: Of 43 
insecticide-based vector control strategies they examined, all interventions caused the 
emergence of insecticide resistance, which will increase the magnitude of future dengue 
epidemics when coupled to loss of herd immunity (Luz et al., 2011). In essence, dengue 
vector control is effective when interventions use a community-based and integrated 
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approach that is tailored to local conditions and combined with educational programs 
(Erlanger et al., 2008). 
In addition, anti-dengue therapeutics have also been developed in tandem with the use 
of vector control methods in the fight against dengue. These can broadly be divided into 
2 categories: Vaccines and antiviral drugs.  
Dengue vaccines are an attractive approach as a prophylactic measure to prevent disease 
progress upon infection. In addition, the possibility of using vaccination to achieve herd 
immunity to reduce the risk of outbreaks is also an attractive one (Durham et al., 2013). 
However, among other challenges, detractors have warned about the lack of 
understanding of issues and risks regarding the prevalence and mechanism of ADE 
associated with DENV infections, as well as the possibility of a recombination between 
attenuated live vaccine strains and wild-type viruses leading to the former reverting to a 
virulent form. 
The search for dengue antivirals has been gaining momentum due to significant 
progress in the structural biology of dengue virus. The primary aim for the development 
of an antiviral drug against dengue is to substantially lower the viral load in patients 
upon administration. In light of the fact that clinical studies have shown that patients 
who suffer from DHF/DSS is significantly higher than that of patients suffering from 
mild dengue fever (Vaughn et al., 2000), it is hoped that the early administration of an 
antiviral that targets essential steps in virus replication can lower viremic levels and 
prevent disease progress and morbidity. 
As neither prophylactic vaccines nor antivirals are available for treatment of dengue 
infection, medical intervention has focused largely on the provision of haemodynamic 
support to compensate for plasma leakage, as well as the relief of clinical symptoms. 
However, considering the increasing global burden of dengue disease, there is thus an 
urgent need for the development of anti-dengue therapeutics. In this study, the discovery 
of antiviral drugs against dengue will be focused upon.  
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1.4.1  Ideal characteristics of dengue antiviral drug 
The development process of a good antiviral drug for dengue maximizes several factors: 
1. Inhibits viral replication significantly 
The ultimate goal of an antiviral drug would be the complete eradication of virus 
from its host. However, in practice, a 50 – 90% inhibition of viral replication 
could be sufficient enough to bring the viral load down to a controllable level for 
host immune system clearance (Botting and Kuhn, 2012). 
2. Specific to virus 
Non-specific targeting of the drug can lead to detrimental adverse effects, or 
even cell death. The targeting of a unique viral-specific protein that is usually 
not present in uninfected host cells could be a possible way to avoid such 
complications. 
3. Targets well-conserved regions 
The targeting of well-conserved regions in the virus minimizes the risk of viral 
escape mutations arising and consequent resistance against the drug. 
4. Broad-spectrum inhibition 
The ability of the drug to effectively inhibit numerous viruses from the same 
Flaviviridae family would fill the void caused by the lack of antivirals for 
flavivirus infections. 
5. Readily enters cells 
An ideal drug should readily be brought into cells, either through passive 
diffusion or active transport. As most drugs are absorbed by passive diffusion 
across a biological barrier (eg. cell membranes), drugs that are small molecules 
with low molecular weights are preferable (Brenner and Stevens, 2010). 
6. Fast-acting 
A major challenge facing the implementation of anti-dengue drugs is the short 
duration window of viremia (Low et al., 2011). 
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1.5  NS5: An attractive anti-dengue drug target 
With new knowledge added to our understanding of the molecular clockwork of DENV, 
prospective drug targets continue to emerge, especially for DENV NS proteins. This 
could possibly be due to a greater conservation of NS proteins compared to structural 
proteins as studies have revealed that 95.5% of conserved sequences in DENV are from 
NS proteins (Khan et al., 2008). This is further backed up by the trend that small 
molecules targeting NS proteins have increasingly been tested on both mouse and cell 
culture models (Bente and Rico-Hesse, 2006). 
Of all the NS proteins encoded by the DENV genome, both NS3 and NS5 proteins have 
been highly regarded as sound targets for drug intervention. This may be attributed to 2 
reasons. Firstly, the functional domains located in these two proteins are essential for 
the viral life cycle. Secondly, as these two proteins are also desirable for the 
development of high throughput assays as they possess enzymatic activity.  
Antiviral efforts in counteracting human immunodeficiency virus (HIV) infections have 
brought to light two important lessons for the development of antivirals. With a myriad 
of drug classes available against HIV (reverse transcriptase inhibitors and protease 
inhibitors), the importance of targeting an essential viral gene critical for the viral life 
cycle is stressed. This criterion is met in both NS3 and NS5 as targets as both proteins 
exhibit multiple enzymatic activities that are indispensable for DENV replication. 
Furthermore, the limited success in antiretroviral therapy has been attributed to acquired 
drug resistance of HIV (Zdanowicz, 2006). As this occurs due to the high rate of viral 
replication coupled to the lack of proof-reading ability of reverse transcriptase which 
result in high mutation rates of the virus, attempts to take advantage of functional and 
structural constraints of the virus has led to the search for sequence conservation in 
viruses for exploitation (Snoeck et al., 2011). When brought into the context of 
choosing a more appropriate between NS3 and NS5 proteins as a viral target, NS5 is 
clearly a more preferable choice as it is the most conserved DENV protein, with NS5 
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proteins across the 4 DENV serotypes sharing almost 70% in amino acid sequence 
homology (Xu and Wang, 1991). A study by Khan et. al. revealed that out of 44 pan-
DENV sequences (highly conserved sequences in all 4 serotypes of DENV) of at least 9 
amino acids, approximately 40% of these were located in NS5 protein. The largest 
spanning pan-DENV sequence was also found in NS5, extending a total of 215 amino 
acids, equating to ~24% of the protein (Khan et al., 2008). As conserved sequences are 
likely to represent critical sites and domains, these regions are less likely to be amenable 
to mutations for viral escape, hence lowering the possibility of viral resistance (Valdar, 
2002). 
A desirable property of an anti-dengue drug would be the broad-spectrum inhibition 
against a wide range of other flaviviruses. Out of 44 sets of highly conserved DENV 
sequences, 27 were found in as many as 64 other viruses in the family Flaviviridae 
(representatives that are human pathogens include WNV, St. Louis encephalitis virus, 
JEV and YFV) and 13 of these represented sequences in NS5, suggesting that an 
inhibitor targeting NS5 could have a higher possibility of being a broad-spectrum 
antiviral. 
The DENV NS5 protein contains two functional domains: A N-terminal MTase and C-
terminal RdRp. MTases play essential roles in both normal physiology and diseases 
through the methylation of nucleic acids and proteins. Due to the high homology of core 
domains of these enzymes, designing specific inhibitors that block only viral-specific 
MTases have been a great challenge as problems with selectivity have arisen because of 
the close resemblance of viral and endogenous MTases. In this aspect, the RdRp would 
be a more practical selection as a drug target since no mammalian homologues of this 
enzyme have been found (Sugiyama et al., 2005). Being a viral-specific protein, drugs 
acting on this protein are less likely to interfere with the normal physiology of host 
cells, or affect them adversely. Moreover, of all conserved sequences found in NS5 
across all 4 DENV serotypes, 60% were found in the RdRp domain, an evident increase 
of 30% from its MTase counterpart (Khan et al., 2008). 
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Over the years, inhibitors against HIV reverse transcriptase, as well as inhibitors against 
polymerases of hepatitis B virus (HBV), cytomegalovirus (CMV) and herpes simplex 
virus (HSV) have been approved as drugs for treatment of associated viral infections 
(Wu et al., 2005). More importantly, this trend is also apparent for inhibitors of the 
closely related HCV NS5B polymerase as Ribavirin has already been approved for use, 
with many others such as Sofosbuvir (completing phase III) in the pipeline currently at 
late phases of clinical trials (Sofia et al., 2010). The flavivirus RdRp is therefore a 
validated target. 
In conclusion, DENV NS5 RdRp presents as an attractive drug target because of its 
position as a viral-specific protein that is highly conserved across all 4 DENV serotypes 
and many flaviviruses. Additionally, this protein also has a vital role in viral RNA 
replication and a great potential as a target in the development of a high-throughput 
enzymatic assay. 
1.6  Types of NS5 RdRp inhibitors 
NS5 RdRp inhibitors fall into two categories: 
a. Nucleoside analogue inhibitors 
These are structurally similar to nucleotides and they work as antimetabolites by 
being incorporated into growing RNA strands. Unlike actual nucleosides, 
nucleoside analogues lack a 3´-hydroxyl group on the deoxyribose moiety, 
which is usually hydrolyzed to form a phosphodiester bond with the next nucleic 
acid. These nucleoside analogues thereby act as chain terminators. However, 
mitochondrial toxicity and other adverse events have been reported as a common 
side effects of the usage of nucleotide analogues, due to structural similarities to 
endogenous nucleosides as well as differential tissue-specific levels of pro-drug 




b. Non-nucleoside inhibitors 
This class of inhibitors may not necessarily bear a structural resemblance to 
nucleosides. Binding to allosteric sites of the NS5 protein, these inhibitors 
change the conformation of the active site such that the protein is no longer 
competent to carry out its RdRp activities (Wang et al., 2003). 
1.7  Conceptualization of project  
1.7.1  Current state of in vitro RdRp assays 
Traditional cell-based drug screening approaches offer benefits in the pursuit of the 
discovery inhibitors as they are usually regarded as one of the closest conditions one can 
get to an in vivo environment. As general screens include numerous targets within a 
single screen, one may even uncover novel targets in the process. However, the key 
drawback associated with this methodology is the time taken for screening, as well as 
meticulous care and great cost into ensuring avoidance of contamination in cell cultures 
with the use of tissue culture facilities. The scaling up of these assays for the use in high 
throughput screening assays has also been a major challenge. Moreover, subsequent 
follow-up screens to further clarify hits are often complex and both labour and resource 
intensive (Westby et al., 2005). 
For these reasons, in vitro enzymatic biochemical assays have long been favored over 
traditional cell-based assays as they allow the concentration on a single target and a set 
of well-defined assays for follow-up purposes (Westby et al., 2005). The relative ease in 
the application of these in high throughput studies has also been a major advantage. 
Following the consensus that DENV NS5 RdRp is a promising drug target, a wide 
myriad of RdRp enzymatic assays in a cell-free setting have been developed. Due to the 
biochemical nature of RdRp in elongating RNA strands, most RdRp assays have utilized 
radioactive labels to track the incorporation of nucleotides. A popular radioactive assay 
format is the scintillation proximity assay (SPA), based on the quantification of 
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radioactivity present on newly transcribed RNA incorporated with radioactive 
nucleotides (Figure 1.5) (Yap et al., 2007). 
 
Figure 1.5 | Scintillation proximity assay for measurement of RdRp activity 
(Adapted from Yap et al., 2007) 
Although these radioactivity-based assays are still widely used, there has been a 
growing inclination to move away from the use of radioactive labels. The motivation 
behind this shift is that radioactive assays for use in high throughput screening studies 
have the aptitude to produce large amounts of waste that can cause health and safety 
concerns. In addition, both the acquirement and disposal of these reagents are costly 
(Seethala and Fernandes, 2001). 
A solution to this is the use of fluorophore-conjugated nucleotides as a substitute to 
radioactive-labeled nucleotides. An example of this is 2'-[(2-benzothiazoyl)-6'-
hydroxybenzothiazole]-ATP (BBT-ATP) (Figure 1.6) (Niyomrattanakit et al., 2011). 
Fluorescence readings can then be taken after nucleotide incorporation which in turn 
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results in the release of fluorophore tags. These measurements would therefore be 
proportional to NS5 RdRp activity. 
 
Figure 1.6 | BBT-ATP (Modified from Jena Bioscience) 
1.7.2  Current state of in vitro DENV NS5 protein production 
DENV NS5 proteins used in in vitro have traditionally been produced by Escherichia 
coli (E. coli) or baculovirus-based systems (Tan et al., 1996). Although NS5 proteins 
yielded from both systems have been shown to have RdRp activity (Niyomrattanakit et 
al., 2010), both protein synthesis systems have many shortcomings. 
For instance, although the E. coli system produces a high yield of proteins rapidly at a 
low cost, a major inherent weakness of it is the lack of post-translational modifications 
present due to it being a prokaryotic-based system. Conversely, although a euykaryotic 
baculovirus system allows for some degree of post-translational modifications, it is both 
an expensive and time-consuming process of up to 10 days. Furthermore, being a cell-
based technique, it is highly susceptible to contamination. 
In recent years, an increasing number of post-translational modifications have been 
discovered for DENV NS5. These include phosphorylation, myristoylation, 
glycosylation and amidation (Khan et al., 2008). With some of these ascertained to be 
important for its function, such as in the study by Bhattacharya et. al. that uncovered 
that the phosphorylation of NS5 at amino acid residue 449 modulates DENV 
replication, there is a pressing need to seek out an alternative NS5 protein synthesis 
system (Bhattacharya et al., 2009). 
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In this study, eukaryotic wheat germ cell-free protein synthesis system is employed to 
produce DENV NS5 protein. Despite being a fairly new system, this protein production 
system is well-established, having generated 13,364 human proteins (encompassing 
70% of the 22,000 human genes). Additionally, 77% of the phosphatases synthesized by 
this system have also showed biological activity (Goshima et al., 2008). 
The wheat germ cell-free protein synthesis system is a rapid method to produce 
proteins, taking one day to produce a large and consistent yield of proteins in a cost-
efficient manner. The technology of this system is outlined in Figure 1.7. 
 
Figure 1.7 | Illustration of the wheat germ cell-free protein synthesis system 
technology (Adapted from CellFree Sciences, Japan) 
Being a eukaryotic system, the wheat germ system has also been shown to allow post 
translational modifications such as glycosylation, acetylation, phosphorylation, iso-
prenylation, myristoylation, complex protein folding and proteolytic processing (Martin 
et al., 1997; Nakamura, 1993; Rubenstein and Chappell, 1983; Zagorski et al., 1983).  




Table 1.1 | A comparison of various in vitro protein synthesis systems 
In this study, DENV-2 NS5 protein synthesized using the wheat germ cell-free protein 
synthesis system will be presented as an alternative to other present protein synthesis 
methods that balances cost, efficiency and physiological relevance. 
1.7.3  Current state of pharmaceutical industry 
In the pharmaceutical industry, it is well-known that productivity has not kept pace with 
increasing research and development (R&D) investments.  
The industry has seen an exponential increase in R&D costs over the decades. However, 
this has not equated to a proportional increase in approved new molecular entities 
(NMEs) (Figure 1.8). This increasing gap between the number of approved NMEs and 




Figure 1.8 | Plot of new chemical entities against R&D spend by the 
pharmaceutical industry in the USA. (Adapted from Samanen, 2012) 
In an increasingly risk-averse world, growing R&D expenses are largely spent in the 
drug discovery and development process which ensues in three overarching stages: 
Discovery phase (new compounds are screened and identified), the preclinical phase 
(compounds are tested in vitro and in animal models), and lastly, the clinical phase 
(drug candidates are tested in humans in trials) (Padhy and Gupta, 2011). 
This increase in R&D costs has been further exacerbated by the high attrition rates of 
drugs from clinical trials, dubbed “the clinical trial cliff”, with the number of drugs 
terminated in Phase III of clinical development doubling in 5 years, reaching 55 
compounds in a 2 year period of 2008 - 2010 (CMR, 2012). The primary reason for 
drop-outs in Phase I and II is safety-related issues, while withdrawals in Phase III are 




Figure 1.9 | The clinical trial cliff (Adapted from Ledford, 2011) 
To combat these problems, the idea of recycling late-phase-failed compounds or already 
marketed drugs to a new indication was sprung. The process of identifying or 
developing new uses for existing or abandoned drugs or compounds is called “drug 
repositioning” (Ashburn and Thor, 2004). This is an appealing prospect from various 
standpoints. 
Firstly, from the industrial standpoint, this course of action can potentially bring in more 
revenue to maximize R&D expenditure. Also, proven formulation and manufacturing 
routes can further reduce additional related investment expenses. 
From an ethical stance, the information generated by existing patient data in clinical 
trials for future indications should be capitalized on to its full potential. 
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Lastly, from the scientific perspective, compounds with established safety and 
bioavailability profiles would undoubtedly get a good head-start in the R&D process. 
These can probably enter clinical trials quicker than NMEs and would less likely fail 
due to human safety and pharmacokinetic issues (Stuart-Kregor, 2007). In addition, a 
well-characterized pharmacology could aid studies into the mechanistic analysis of new 
indications.  
The success stories of several repositioned drugs such as sildenafil (angina to erectile 
dysfunction) and thalidomide (morning sickness to multiple myeloma) have been well 
chronicled (Novac, 2013). More recently, mifepristone, initially approved as an 
abortifacient, has also been repurposed as treatment for Cushing’s syndrome in early 
2012 (Castinetti et al., 2012). These case studies are indicative of the recognition of the 
increasing importance of drug repositioning today.  
Brought into the context of this study, these principles were a guide into the selection of 
screening library to utilize. For the various reasons aforementioned, a library of the US 
Food and Drug Administration (FDA)-approved drugs was opted for. In addition, to 
further expand this screening library, natural compounds, some of which are used as 
health supplements, were also appended.  
Natural compounds, often used in traditional medicine, were chosen for their better 
safety and tolerance profiles compared to synthetic compounds or general NMEs 
(Patwardhan and Vaidya, 2010). This is probably the reason why over 60% of anti-
cancer and 75% of anti-infective drugs approved from 1981 - 2002 can be traced back to 
natural origins (Gupta et al., 2005). 
The screening of FDA-approved drugs and natural compounds in an in vitro assay 
presents as a safer starting point as FDA-approved drugs, for example, would have 
passed all in vivo toxicity testing successfully. The choice of using safe drugs and 
compounds for screening would ideally accelerate the follow-up cell-based evaluation 
and drug repositioning process significantly. The importance of this sentiment has been 
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echoed in recent efforts as several promising anti-DENV compounds exhibited 
unfavourable high toxicity in vivo (Chen et al., 2010; Yin et al., 2009) (Section 1.7.4 ). 
1.7.4  Recent advances in anti-DENV drug discovery 
Much of anti-dengue drug discovery still remains in its infant stages of identification 
potential antiviral candidates. Small molecules or repositioned drugs that have been 





Name Target Cellular activity Reference 
CC50 (µM) EC50 (µM) 
Entry inhibitors 
ST-148 C protein >100 0.016 (Byrd et al., 2013a) 
LCTA-949 Unspecified >25 6.9 (De Burghgraeve et al., 
2012) 
1662G07 E protein >100 16.9 (Schmidt et al., 2012) 
SA-17 E protein 43 0.52 (Kaptein et al., 2010) 
NITD-448 E protein 48.7 9.8 (Poh et al., 2009) 
NS3 inhibitors 
ST-610 Helicase >100 0.272 (Byrd et al., 2013b) 
Ivermectin Helicase 3.8 0.7 (Mastrangelo et al., 
2012) 
Compound 23i Protease >100 24.7 (Deng et al., 2012) 
Aminobenzamide Protease No data No data (Aravapalli et al., 
2012) 
Compound 32 Protease >100 <10 (Steuer et al., 2011) 
BP2109 Protease 29.28 0.17 (Yang et al., 2011) 
NS5 inhibitors 
Compound 10 MTase No data No data (Lim et al., 2011) 
Balapiravir RdRp No data 1.9 (Nguyen et al., 2013) 
NITD-107 RdRp No data No data (Noble et al., 2013) 




RdRp >50 2.61 (Chen et al., 2010) 
NITD-008 RdRp >100 0.64 (Yin et al., 2009) 
Table 1.2 | Summary of recently discovered anti-DENV small molecules and drugs 
 
In particular, RdRp inhibitors are of significant interest in this study and will be further 
discussed. Most recently, balapiravir, originally developed for HCV treatment and later 
terminated due to adverse hematological effects in patients (Nelson et al., 2012), was 
repositioned as an anti-DENV drug for a Phase II trial after its anti-DENV efficacy in 
both DENV replicon and human peripheral blood mononucleated cells (PBMCs) were 
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established in vitro (Nguyen et al., 2013). Unfortunately, balapiravir was not shown to 
improve the clinical and virological parameters of patients, and a possible reason could 
be that higher plasma levels of the drug are required for the drug to exert antiviral 
effects. 
A large proportion of anti-dengue drug discovery has been led by Novartis Institute for 
Tropical Diseases (NITD), an effort that has led to the development of many high 
throughput assays to screen their library of 1.8 million compounds. Not surprisingly, a 
significant number of RdRp inhibitors have been discovered. The most promising 
DENV NS5 RdRp inhibitors (NITD-008, NITD-449 and NITD-203) were found to have 
high inhibitory effects and low cytotoxicity in vitro. However, all exhibited high 
toxicity in in vivo studies and advancement to drug development were halted. For 
instance, although the treatment of DENV-infected mice with NITD-008 suppressed 
peak viremia significantly, toxicological testing through extended oral dosing for 2 
weeks in rats and dogs resulted in severe side effects (Chen et al., 2010; Yin et al., 
2009). As high toxicity of antiviral molecules can form significant stumbling blocks to 
the development of anti-DENV RdRp inhibitors, this further lends weight to the 
approach of this study to screen libraries of FDA-approved drugs and natural 




1.8  Specific aims of project 
i. Synthesis of high quality DENV-2 NS5 full-length and RdRp domain mutant 
proteins by utilizing the wheat germ cell-free protein synthesis system 
ii. Application of a fluorescence-based in vitro NS5 RdRp screening assay to 
wheat germ cell-free system-derived NS5 protein 
iii. Identification of inhibitors against DENV NS5 by screening libraries of 
FDA-approved drugs and natural compounds using primary in vitro NS5 
RdRp assay 
iv. Further validation of candidate drugs/compounds from primary screening 
assay in secondary in vitro assay  
v. Evaluation of inhibitory effect of candidate drugs/compounds in cell-based 
DENV infection system by exploring their cytotoxicity and capacity to 
reduce viral titers 
vi. Demonstration that anti-DENV effects of best candidate drug/compound are 
reproducible in a cell-type and assay-independent manner 





Chapter 2. Materials and Methods 
2.1  Wheat germ cell-free protein expression 
2.1.1  Construction of template plasmid DNAs 
The cDNA encoding the full-length DENV-2 NS5 protein (900 amino acids) or C-
terminal RdRp domain mutant (amino acid 405 - 900 of DENV-2 NS5) were obtained 
by amplification from a plasmid with a pDVWS601 backbone containing the replicon 
cDNA of DENV subtype 2, New Guinea C (NGC) strain via PCR (Ng et al., 2007). The 
resulting cDNA were then inserted into the pEU-E01-GST-TEV-MCS vector (CellFree 
Sciences, Japan), generating the expression plasmids for N-terminal GST-fused NS5 
(pEU-GST-NS5) and GST-fused RdRp (pEU-GST-RdRp) respectively. As a negative 
protein control, a bacterial protein, the dihydrofolate reductase (DHFR) (GST-DHFR) 
was used. 
2.1.2  In vitro transcription 
Cell-free protein expression was executed using the wheat germ cell-free protein 
expression system (CellFree Sciences). Using the template plasmids obtained (pEU-
GST-NS5, pEU-GST-RdRp, pEU-GST-DHFR), in vitro transcription (IVT) to obtain 
mRNA was carried out according to the manufacturer’s protocols. In brief, IVT was 
carried out in a 250 µl reaction mixture (1X Transcription buffer, 2.5 mM NTP mix, 
1U/µl RNase inhibitor, 1U/µl SP6 RNA polymerase, 100 ng/µl respective cell-free 
expression plasmid) and incubated for 6 h. Following which, the mRNA quality was 
checked by method of gel electrophoresis by resolving samples with a 1% agarose gel. 
2.1.3  In vitro translation 
In vitro translation via a bilayer method was then performed with the mRNA obtained. 
The bottom layer reaction mixture (500 µl) including in vitro transcribed mRNA, 120 
OD/ml WEPRO®1240G, and 40 ng/µl creatine kinase was first made and later added to 
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a well of a 6-well plate containing 5.5 ml 1X SUB-AMIX®. The bilayer reaction was 
incubated for 16 h at 16°C (CellFree Sciences). 
2.1.4  Protein affinity purification 
Affinity purification of cell-free recombinant proteins was performed using Protemist 
DTII, an automated robotic protein synthesizer (CellFree Sciences). Firstly, the crude 
protein (cell-free translation mixture after 16 h incubation at 16°C) was mixed with 200 
mM NaCl and 10 mM DTT and incubated with Glutathione Sepharose Fast Flow beads 
(GE Healthcare) for 2 h with mild rocking. After 3 rounds of washing by PBS, the GST-
tagged recombinant proteins were then eluted with elution buffer (50 mM Tris-HCl, pH 
8.0, 50 mM NaCl, 10 mM reduced glutathione, 10% glycerol) yielding the purified 
protein. 
2.1.5  Buffer exchange 
As the presence of reduced glutathione in the purified protein could affect downstream 
assays, purified proteins by Protemist DTII were further subjected to buffer exchange by 
fast protein liquid chromatography (FPLC) using a HiTrap Desalting column (GE 
Healthcare). These were eluted with a protein buffer (20 mM Tris-HCl, pH 7.5, 50 mM 
NaCl, 10% glycerol). 
2.1.6  Protein concentration 
Proteins were then concentrated approximately 20-fold with Amicon Ultracentrifugal 
filters (Millipore). Next, protein concentration was determined using QuickStart 
Bradford Protein Assay (Bio-Rad) using bovine serum albumin (BSA) as a protein 
standard. 




2.1.7  CBB analysis 
To determine the purification efficiency of the recombinant proteins, samples from 
various purification steps were subjected to Coomassie brilliant blue (CBB) staining. 
The samples were added to an equal volume of sample of 2X sodium dodecyl sulfate 
(SDS) buffer (125 mM Tris-HCl, pH 6.8, 4% SDS, 0.2% bromophenol blue, 20% 
glycerol, 200 mM β-mercaptoethanol) and boiled at 98°C for 10 min.  
The samples were then resolved by SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) with a 10% acrylamide gel. Electrophoresis was performed using running buffer 
(25 mM Tris, 192 mM glycine, 0.1% SDS) at 25 mA for 1 h.  
After SDS-PAGE concluded, the gel was washed briefly with water and fixed by 
incubation with CBB fixing solution (50% methanol, 10% glacial acetic acid) for 10 
min with gentle shaking. This was repeated three times, followed by staining with Quick 
CBB Plus (Wako Pure Chemical Industries, Japan) for 30 min. The gel was then de-
stained in water with gentle shaking and brief microwaving every 30 min to facilitate 
the process. 
Pre-stained and unstained molecular weight markers (Thermo Fisher Scientific) were 
also loaded to track SDS-PAGE protein migration and CBB staining efficiency 
respectively. 
2.1.8  Western blotting analysis 
The samples were added to an equal volume of sample of 2X SDS buffer (125 mM Tris-
HCl, pH 6.8, 4% SDS, 0.2% bromophenol blue, 20% glycerol, 200 mM β-
mercaptoethanol) and boiled at 98°C for 10 min.  
The samples were then resolved by SDS-PAGE with a 10% acrylamide gel. 
Electrophoresis was performed using running buffer (25 mM Tris, 192 mM glycine, 0.1% 
SDS) at 25 mA for 1 h. Resolved proteins were transferred onto a polyvinylidene fluoride 
(PVDF) membrane (Millipore) at 120mA/membrane for 70min. After blocking with 5% 
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BSA dissolved in 0.05% phosphate-buffered saline-Tween 20 solution (PBS-T, 0.05% 
Tween-20 in PBS), immunoblots were performed using monoclonal rabbit anti-NS5 
antibody (1:2000, GeneTex) dissolved in 3% BSA/PBS-T. Secondary horseradish 
peroxidase-conjugated goat anti-mouse IgG secondary antibodies (1:2000, Cell Signaling 
Technology) dissolved in PBS-T were then used to probe primary antibody binding, 
followed by detection with Western Lightning® Pro enhanced chemiluminescence (ECL) 
reagent (Perkin-Elmer). Protein band imaging was performed by ImageQuant LAS4000 
mini (GE Healthcare) and analysis was conducted using ImageQuant™ TL software (GE 
Healthcare). 
2.2  Preparation of drugs and compounds 
2.2.1  Drug/Compound libraries for primary screening assay 
The FDA-approved drug library comprised of 640 drugs (ENZO Life Sciences) and was 
kindly provided from Professor Chang Young-Tae (Department of Chemistry, NUS). 
The natural compound library was a combination compounds extracted by Dr. 
Yoshiyuki Yoshinaka (Tokyo Medical and Dental University, Japan) and health 
supplements from Goodcare Pharma. All drugs and compounds in the libraries were 
kept at a stock concentration of 400 µg/ml in 100% dimethyl sulfoxide (DMSO, Hybri-
Max, Sigma-Aldrich) at -20°C for storage. 
All drugs/compounds were used at a final concentration of 20 µg/ml with 5% DMSO in 
the primary screen using in vitro DENV NS5 RdRp assay. 
2.2.2  Drugs for validation studies 
As drugs in the FDA-approved drug library was limited in quantity and only available in 
low concentrations, hits derived from the primary screening assay were commercially 
obtained and used for further validation studies. In validation studies, several 
compounds were commercially obtained, including oxiconazole nitrate (AK Scientific), 
itraconazole (AK Scientific), tolcapone (AK Scientific), butoconazole nitrate (AK 
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Scientific), lomofungin (ENZO Life Sciences), pinacidil (ENZO Life Sciences) and 
entacapone (Tocris Bioscience). 
All drugs were diluted to a stock concentration of 50 mM with 100% DMSO, aliquoted 
and stored at -20°C. All drugs were freshly diluted for each use. 
2.3  Fluorescence-based in vitro DENV NS5 RdRp assay 
A linear RNA template, 3’UTR-U30 (5’-U30-ACC AGG UUC UAG AAC CUG UU-3’ 
[(Niyomrattanakit et al., 2011), was diluted in TE buffer and incubated at 60°C for 5 
min. Next, it was left at room temperature for a further 60 min to induce the formation 
of an intramolecular short hairpin structure. This hairpin RNA template mimics the 3’ 
untranslated (UTR) region of the DENV genome and is a substrate of DENV NS5 
protein.  
To kick-start the in vitro assay, 100 nM hairpin RNA template and 25 nM GST-NS5, 
GST-RdRp or negative control protein (GST-DHFR) were pre-incubated in RdRp assay 
buffer (50 mM Tris-HCl, pH 7.0, 2 mM DTT, 10 mM KCl, 1 mM MnCl2, 0.01% 
Triton-X-100) in a total volume of 10 µl for 30 min in individual wells of a black 384-
well plate (Corning) to allow binding of protein to RNA template.   
After the pre-incubation, drugs/compounds from the screening libraries were added. 
This was followed by the further addition of 2 µM BBT-ATP (Jena Bioscience, 
Germany) to initiate hairpin RNA template-dependent RNA polymerization. After 
addition of all reagents, the plate was shaken at high speed for 20 s using iMark 
Microplate Reader (Bio-Rad).  This template-dependent RNA polymerization was 
carried out in a total volume of 20 µl for 2 h at room temperature.   
Next, 10 µl of 1 ng/µl calf intestinal alkaline phosphatase (CIAP, Promega) buffered in 
150 mM Tris-HCl pH 9.3, 300 µM MgCl2 was added to the reaction mixture. The plate 
was shaken for 20 s at high speed using iMark Microplate Reader and incubated in the 
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dark for 1 h for the liberation of BBT from BBT-PPi, a by-product of the incorporation 
of the nucleotide analogue into the growing RNA strand. 
Liberated BBT was measured by Synergy H1 hybrid microplate reader (Biotek) at an 
excitation wavelength of 422 nm and an emission wavelength of 566 nm 
(Niyomrattanakit et al., 2011; Takahashi et al., 2012). 
2.4  Cell culture 
2.4.1  General growth and maintenance 
Human hepatocellular carcinoma cells, Huh-7.5 (Nakabayashi et al., 1982), was 
maintained in Dulbecco's modified Eagle medium (DMEM) (Biowest) supplemented 
with 10% heat inactivated fetal bovine serum (FBS, Invitrogen) and antibiotics (100 
U/ml penicillin and streptomycin, Invitrogen). Baby hamster kidney cell, BHK-21, was 
maintained in RPMI 1640 (Biowest) supplemented with 10% FBS and antibiotics. 
Rhesus monkey kidney cells, LLC-MK2, was maintained in Eagle's minimal essential 
medium (EMEM) (Sigma-Aldrich) supplemented with 10% FBS, antibiotics and 2 mM 
L-glutamine (Sigma). BHK-21 cells harbouring a DENV subgenomic replicon with a 
luciferase reporter (Ng et al., 2007) were maintained in DMEM supplemented with 10% 
FBS, antibiotics, and 3 µg/ml puromycin (Invitrogen). Aedes albopictus mosquito cells, 
C6/36 cells, were maintained in RPMI 1640 supplemented with 8% FBS and antibiotics. 
The cells were cultured in a 37°C incubator with a 5% CO2 atmosphere, with the 
exception of C6/36 cells in a 28°C incubator. The culture medium was refreshed every 
three days. When confluence was reached, cells were washed once with phosphate 
buffered saline (PBS) before trypsinization. One milliliter of 0.25% trypsin/1 mM 
EDTA solution (Invitrogen) was added for trypsinization, before 9 ml of complete 
medium was combined to inactivate trypsin. Cells were spun down at 1,500 rpm for 5 




2.4.2  Viruses preparation 
A DENV-2 strain (Singapore isolate EDEN2) isolated in Singapore(Low et al., 2006), 
which was kindly provided by Professor Subhash Vasudevan from Duke-NUS, was 
inoculated into C6/36 cells at multiplicity of infection (MOI) 0.1 for amplification and 
the cells were maintained in RPMI 1640 containing 8% FBS and antibiotics. At 5 days 
post-inoculation, the supernatant was filtered to remove cell debris, aliquoted and stored 
at -80°C. 
For the titration of virus stock, plaque assay was performed. BHK-21 cells were seeded 
at a density of 8 x 10
5
 cells in each well of a 6-well plate. The next day, serial dilutions 
of 10 µl of viral supernatant were used to infect the BHK cells in 1 ml serum-free RMPI 
media. Infection was carried out for 1 h at 37°C with gentle rocking every 15 min. After 
which, the infection media was replaced by plaque assay overlay media (0.8% 
methylcellulose [Sigma], 2% FBS, 100 U/ml penicillin and streptomycin in RPMI 
1640). After 5 days, the overlay media was removed and cells were washed twice with 
PBS. This was followed by fixation using 4% paraformaldehyde (PFA, Wako Pure 
Chemical Industries, Japan) for 20 min at room temperature, washing in running water 
for 5 min and staining with 1% crystal violet (Sigma) for another 20 min at room 
temperature. After a further washing step and drying of plates, plaques were enumerated 
and viral titers were determined. This virus stock was used for the infection of Huh-7.5 
cells. 
For the infection of LLC-MK2 cells, all four serotypes of DENV including DENV-1 
(Singapore isolate S144), DENV-2 (NGC strain), DENV-3 (Singapore isolate EDEN 
130/05) and DENV-4 (Singapore isolate S8976) were kindly provided by Dr. Justin Chu 
(Department of Microbiology, NUS). Likewise, these viruses were propagated in C6/36 
cells and the cells were maintained in RMPI 1640 (8% FBS, 100 U/ml penicillin and 
streptomycin). At 5 days post-inoculation, the supernatant was centrifuged to remove 
cell debris. If concentration of virus was necessary, the viral supernatants were loaded 
onto a 30% sucrose cushion and centrifuged for 16 h at 100, 000 xg at 4°C. The virus 
 45 
 
fraction obtained was then re-suspended in PBS, aliquoted and stored at -80°C. The 
viral titers were determined by plaque assay and used for the infection of LLC-MK2 
cells. 
2.5  Validation of inhibition of DENV replication by drug/compound in cell-
based infection system 
2.5.1  Cell viability assay 
Huh-7.5 cells were seeded at a density of 2 x 10
4
 cells in each well of a white, clear 
bottom 96-well plate (Corning). After 24 h of incubation, the culture media was 
removed and replaced with a wide concentration range of drugs/compounds diluted in 
DMEM to a final DMSO concentration of 0.5%.  
Forty-eight hours later, 100 µl of supernatant was removed. 100 µl of CellTiter-Glo 
Luminescent Cell Viability Assay reagent (Promega) was then added and the plate was 
shaken at 600 rpm for 3 min. After further 10 min incubation in the dark, luminescence 
readings directly proportional to the amount of ATP released were taken with Synergy 
H1 hybrid microplate reader (Biotek).  
2.5.2  Infection assay: Reduction of viral titer by drug/compound 
Huh-7.5 cells were seeded at a density of 2 x 10
4
 cells in each well of a white, clear 
bottom 96-well plate. After 24 h of incubation, the culture media was removed and 
replaced with a different concentration of drugs/compounds to a final DMSO 
concentration of 0.5%. Simultaneously, the cells were also infected with DENV-2 at a 
MOI of 0.1. After an incubation of 48 h, viral supernatants were collected and stored at -
80°C till use. 




BHK-21 cells were seeded at a density of 8 x 10
5
 cells in each well of a 6-well plate. 
The next day, 10 µl of viral supernatant was used to infect the BHK-21 cells in 1 ml 
serum-free RPMI 1640 media. Infection was carried out for 1 h at 37°C with gentle 
rocking every 15 min. After which, the infection media was replaced by plaque assay 
overlay media (0.8% methylcellulose, 2% FBS, 100 U/ml penicillin and streptomycin in 
RPMI 1640). After 5 days, the overlay media was removed and cells were washed twice 
with PBS. This was followed by fixation using 4% PFA for 20 min at room 
temperature, washing in running water for 5 min and staining with 1% crystal violet for 
another 20 min at room temperature. After a further washing step and drying of plates, 
plaques were enumerated and viral titers were determined. 
2.5.3  Calculation of selectivity index (SI) 
The values obtained for both cell viability assays and viral titer determination via plaque 
assays were processed and expressed as a relative percentage against the readings for 
0.5% DMSO control in each assay. 
CC50 (concentration of a drug that causes 50% cell death) and EC50 (effective 
concentration of a drug that inhibits 50% of viral replication) were then calculated from 
cell viability assays and plaque assays respectively.  
From these values, the selectivity index (SI = CC50/ EC50) of the various drugs were 
derived. Selectivity index of an effective drug/compound should be greater than 1. The 
higher a drug’s SI is, the wider the window is between an effective dose from a 
cytotoxic dose, and hence, the greater its potential as a drug. 
2.6  Cytopathic effect (CPE)-based anti-dengue assay 
This assay was developed based on the cytopathic effect (CPE) of DENV-2 infection 
seen in LLC-MK2 cells and anti-dengue activity of a drug/compound is characterized 
by the rescue of cells from infection-induced cell death (Ichiyama et al., 2013). 
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LLC-MK2 cells were seeded in a 96-well plate at a density of 2 x 10
3
 cells per well one 
day prior to the start of the assay. After 24 h, cell culture media was replaced with a 
range of concentrations of the test drug/compound diluted in EMEM. Following which, 
half the set of cells were inoculated with DENV-2 at MOI 0.5, while the other half 
remained as a mock infected control. The cells were then allowed to proliferate. 
After 5 days of infection, a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay was performed to determine the number of viable cells present 
(Mosmann, 1983). In brief, 20 µl of 5 mg/ml stock MTT solution (Sigma) was added 
into each well and incubated for 1 h at 37°C. Next, acid-isopropanol (0.04 N HCl in 
isopropanol) was added, and further incubated at room temperature for 1 h with shaking. 
Fluorescence readings were then taken using Infinite 200 Microplate Reader (Tecan). 
2.7  Plaque reduction assay 
The plaque reduction assay tests the ability of a drug/compound to reduce viral titer at 
non-cytotoxic doses in LLC-MK2 cells. 
LLC-MK2 cells were seeded in a 6-well plate at a density of 3 x 10
5
 cells per well one 
day prior to the start of the assay. After 24 h, cell culture media was replaced with an 
inoculation of 100 plaque forming units (PFU) of DENV, followed by a range of 
concentrations of drugs/compounds (final DMSO concentration of 0.5%) diluted in 
plaque assay overlay media (0.8% methylcellulose, 10% FBS and antibiotics in 
EMEM). 
At 5 days post-inoculation, the overlay media was removed and cells were washed twice 
with PBS. This was followed by fixation using 4% PFA for 20 min at room 
temperature, washing in running water for 5 min and staining with 1% crystal violet for 
another 20 min at room temperature. After a further washing step and drying of plates, 
plaques were enumerated and viral titers were determined. 
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2.8  Time of addition assay 
LLC-MK2 cells were seeded in a 6-well plate at a density of 3 x 10
5
 cells per well one 
day prior to the start of the assay. Twenty-four hours later, the cells were inoculated 
with 100 PFU of DENV-2 at 4°C for 1.5 h. After the cells were washed with ice cold 
PBS thrice, the plates were shifted for culturing in a 37°C incubator. Kusunoki (50 
µg/mg) diluted in plaque assay overlay medium (0.8% methylcellulose, 10% FBS and 
antibiotics in EMEM) was added to the cells at different time points pre- and post-
infection (-1.5, 0, 1, 2, 3, 4 and 5 h). Heparin (100 µg/mg), a known entry inhibitor of 
DENV, was used as a positive control (Lin et al., 2002), while DMSO was used as a 
negative control.  
At 5 days post-inoculation, the overlay media was removed and cells were washed twice 
with PBS. This was followed by fixation using 4% PFA for 20 min at room 
temperature, washing in running water for 5 min and staining with 1% crystal violet for 
another 20 min at room temperature. After a further washing step and drying of plates, 
plaques were enumerated. 
2.9  Binding assay 
LLC-MK2 cells were seeded in a 6-well plate at a density of 3 x 10
5
 cells per well one 
day prior to the start of the assay. Twenty-four hours later, the cells were inoculated 
with 200 PFU of DENV-2 at 4°C or 37°C for 1.5 h with gentle rocking every 5 min in 
the presence of kusunoki (50 µg/mg). DMSO was used as a negative control. After the 
cells were washed with ice cold PBS thrice, plaque assay overlay medium (0.8% 
methylcellulose, 10% FBS and antibiotics in EMEM) was added to the wells.  
At 5 days post-inoculation, the overlay media was removed and cells were washed twice 
with PBS. This was followed by fixation using 4% PFA for 20 min at room 
temperature, washing in running water for 5 min and staining with 1% crystal violet for 
another 20 min at room temperature. After a further washing step and drying of plates, 
plaques were enumerated. 
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2.10  DENV replicon luciferase assay 
BHK-21 cells containing a DENV subgenomic replicon with a luciferase reporter gene 
(Ng et al., 2007) were seeded in a 6-well plate at a density of 2.5 x 10
5
 cells per well one 
day prior to the start of the assay and weaned off the puromycin usually included in 
culturing media to maintain the DENV replicon. Twenty-four hours later, the cells were 
treated with kusunoki (40µg/ml) diluted in DMEM. NITD-008 (10, 20, 50 µg/ml), a 
known DENV RdRp inhibitor, was used as a positive control (Yin et al., 2009).  
After an incubation of 48 h, the cells were washed briefly with PBS and harvested. After 
a lysis step using M-PER (mammalian protein extraction reagent, Thermo Fisher 
Scientific) with shaking for 5 min, the cells were spun down at 14,000 xg for 15 min. 
The supernatant was then transferred to a new tube and used for analysis.  
For luciferase assay, the renilla luciferase assay system (Promega) was utilized. In brief, 
100 µl of reagent was added to 20 µl of cell lysate. Luciferase activity was measured 




Chapter 3. Results 
3.1  Production of DENV-2 NS5 protein by wheat germ cell-free protein 
synthesis system 
The first aim of the project is to present DENV-2 NS5 protein made using the wheat 
germ cell-free protein synthesis system as a useful alternative to conventional protein 
production methods (eg. E. coli, baculovirus systems) that balances cost, efficiency and 
physiological relevance. 
Full-length NS5 (GST-NS5), its C-terminal RdRp domain mutant (GST-RdRp) and a 
negative control protein (GST-DHFR) were synthesized using the wheat germ cell-free 
system. A schematic illustration (Figure 3.1a) outlines the protein production method 
and the downstream purification steps taken. 
To determine the purification efficiency of the recombinant proteins, GST-NS5 protein 
samples from various purification steps (crude, purified, purification flow-through and 
desalted) were subjected to CBB staining. A representative CBB staining (Figure 3.1b) 
is shown. In the crude sample, a protein band of the correct size (133 kDa) was seen 
(lane 2). However, in addition to the protein of interest, many unspecific protein bands 
were seen, most possibly due to the abundance of endogenous proteins present in the 
wheat germ endosperm. After affinity purification using glutathione sepharose beads, 
the purified sample showed a single band of approximately 133 kDa (lane 3), 
representing high purification efficiency, although some protein of interest could 
possibly have been lost, as detected by a band of the same size in the purification flow-
through (lane 4). As the presence of reduced glutathione in the purified protein could 
affect downstream assays, purified GST-NS5 proteins were further purified using a 
desalting column. This process did not affect the purity of the sample, as seen in the 
single band of the purified sample (lane 5). However, as the purified sample was diluted 
in the purification buffer (faint band), concentration of the protein was performed. In 
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addition, western blotting analysis also showed specificity of the NS5 protein produced 





Figure 3.1 | Production of GST-NS5, GST-RdRp and GST-DHFR proteins by 
wheat germ cell-free protein synthesis system 
a) Schematic illustration of the protein production procedure. pEU-based 
plasmid DNAs (pEU-GST-NS5, pEU-GST-RdRp and pEU-GST-DHFR) were 
used as templates for in vitro transcription step of wheat germ cell-free protein 
synthesis system. mRNA transcripts obtained were then used for in vitro 
translation via a bilayer method, yielding crude protein mixtures. The crude 
proteins were then subject to affinity purification first by glutathione sepharose 
beads (GE Healthcare), subsequently eluted with reduced glutathione in an 
automated robotic system, Protemist DTII (CellFree Sciences). As the presence 
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of reduced glutathione in the protein sample could affect downstream assays, 
purified proteins were further subjected to buffer exchange using a desalting 
column. Proteins were then concentrated. 
b) CBB staining analysis of GST-NS5 from various purification steps. Protein 
samples including GST-NS5 from various purification steps (crude [lane 2], 
purified [lane 3], purification flow-through [lane 4] and buffer-exchanged [lane 
5]) were subjected to SDS-PAGE analysis and stained with CBB.  
c) Western blotting analysis of GST-NS5. Purified GST-NS5 was subjected to 
SDS-PAGE and blotted with anti-NS5 antibody (lane 1). 
d) CBB staining analysis of GST-DHFR. Purified GST-DHFR (negative control 




3.2  Development of fluorescence-based DENV NS5 RdRp assay using wheat 
germ cell-free system-produced NS5 proteins 
The fluorescence-based in vitro assay measures the RdRp activity of DENV NS5 
protein (Niyomrattanakit et al., 2011; Takahashi et al., 2012). A hairpin RNA 
mimicking the 3’ UTR region of DENV was first prepared. This hairpin RNA served as 
a template for NS5 to bind to, and elongate the RNA strand with an available nucleotide 
pool containing a nucleotide analogue, BBT-ATP. After an incubation period to allow 
for RNA synthesis, CIAP was added to liberate of BBT from BBT-PPi, a by-product of 
the incorporation of the nucleotide analogue into the synthesizing RNA strand. The 
liberated BBT was measured by Synergy H1 hybrid microplate reader. 
To clarify the specificity of the NS5 RdRp assay, core assay constituents were removed 
separately. As shown in Figure 3.2a, this included reactions with no proteins (i.e. 
protein buffer alone was added in place of GST-NS5), no MnCl2 (RdRp cofactor) and 
no nucleotide analogue BBT-ATP respectively. These were then compared to the 
reaction with the full reagent mix (GST-NS5). Both the no protein and no BBT-ATP 
reactions display minimal background RdRp activity at approximately 10% and 1% 
respectively. Without the cofactor of RdRp, MnCl2, NS5 RdRp activity was decreased 
to about 40% (Figure 3.2a). Fifty micromolar of NITD-008, a reported DENV RdRp 
inhibitor (Yin et al., 2009), was also added to the full NS5 RdRp reaction mix as a 
control and inhibited approximately 40% of NS5 RdRp activity. 
To further ensure that the measured fluorescence levels in the in vitro RdRp assay 
correlated to enzymatic activity specific to NS5 protein, the assay was carried out using 
increasing concentration of GST-NS5 (1.56 - 25 nM). A dose-dependent increase in 
fluorescence intensity was seen as the concentrations of GST-NS5 were increased 
(Figure 3.2b). 
The relative RdRp activities of DENV-2 full-length NS5 (GST-NS5) were explored 
using RdRp domain mutant of NS5 (GST-RdRp) and a negative protein control (GST-
DHFR). As expected, DHFR only produced background fluorescence levels of about 
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10%, comparable to the no protein control (Figure 3.2c). Although equal concentrations 
of wild-type (i.e. full-length) and RdRp domain mutant of NS5 proteins were used, the 
RdRp domain mutant protein only achieved approximately 80% of RdRp activity 
compared to full-length NS5 (Figure 3.2c). 
 
Figure 3.2 | Evaluation of fluorescence-based RdRp assay using DENV-2 NS5 and 
DENV-2 RdRp produced by wheat germ cell-free system 
a) Specificity of NS5 RdRp assay. In addition to the reaction with the full reagent 
mix (GST-NS5), core assay constituents were removed. This included reactions 
with no proteins (desalting buffer was added in place of GST-NS5), no MnCl2 
and no nucleotide analogue BBT-ATP, respectively. A reported DENV RdRp 
inhibitor, NITD-008, was also added (50 µM) to the full NS5 RdRp reaction mix 
 56 
 
as a control. All readings were expressed relative to that of full NS5 RdRp 
reaction mix. Results are the mean of 3 independent experiments with error bars 
± sd. 
b) Dose-dependency of NS5 RdRp assay. To ensure that the measured 
fluorescence levels in the in vitro NS5 RdRp assay correlated to RdRp activity 
specific to NS5 protein, increasing GST-NS5 concentrations (1.56 - 25 nM) 
were used in separate reactions. Results are the mean of 3 independent 
experiments with error bars ± sd. 
c) RdRp activities of full-length and RdRp domain mutant of NS5. Twenty five 
nanomolar of GST-NS5 (full-length), GST-RdRp (domain mutant) and GST-
DHFR (negative control), was used in the in vitro RdRp assay. Results are the 





3.3  Screening of FDA-approved drug and natural compound libraries in 
fluorescence-based in vitro NS5 RdRp assay  
After the fluorescence-based RdRp assay using DENV-2 NS5 synthesized by wheat 
germ cell-free system was established, the primary screening of a total of 648 drugs, 
which were composed of 640 FDA-approved drugs (Figure 3.3a) and 8 natural 
compounds (Figure 3.3b), was conducted. These are regarded as safer alternatives to 
experimental synthetic compounds. 
Inhibitors against RdRp activity of RNA viruses developed so far can fall into two 
categories: nucleoside inhibitors and non-nucleoside inhibitors. Nucleoside inhibitors 
are administered as pro-drugs for increased safety, bioavailability and efficacy (Peterson 
and McKenna, 2009). Since they are nucleoside analogues, these have to be 
successively phosphorylated by cellular enzymes such as phosphoglycerate kinase and 
creatine kinase (Cihlar and Ray, 2010) . These are structurally similar to nucleosides 
and they work as antimetabolites by being incorporated into growing RNA strands. 
Unlike actual nucleotides, nucleotide analogues lack a 3´-hydroxyl group on the 
deoxyribose moiety, which is usually hydrolyzed to form a phosphodiester bond with 
the next nucleic acid. These nucleoside analogues thereby act as chain terminators. 
However, mitochondrial toxicity and other adverse events have been reported as a 
common side effects of the usage of nucleoside analogues, due to structural similarities 
to endogenous nucleotides as well as differential tissue-specific levels of pro-drug 
activation (Lund et al., 2007; Noble et al., 2010). Non-nucleoside inhibitors, on the 
other hand, may not necessarily bear a structural resemblance to nucleotides. Binding to 
allosteric sites of the NS5 protein, these inhibitors change the conformation of the active 
site such that the protein is no longer competent to carry out its RdRp activities (Wang 
et al., 2003). 
As majority of the drugs and compounds screened in this study belonged to the FDA-
approved drug library, any inhibitors picked up by the RdRp assay are more likely to be 
non-nucleoside inhibitors. This is because nucleotide analogues in the FDA-approved 
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library would be pro-drugs, and would not have been able to be converted to an active 
triphosphate nucleotide form in an in vitro setting.  
A limitation in using a FDA-approved library of drugs in an in vitro assay would 
therefore be the inevitable inability to pick up drugs which require processing in an in 
vivo setting, such as nucleotide analogues. 
All drugs and compounds were screened at a final concentration of 20 µg/ml in 5% 
DMSO and measurements were expressed relative to 5% DMSO diluent control without 
drugs or compounds. Any drug or compound which inhibited NS5 activity would show 
a lower fluorescence intensity compared to the control reaction containing 5% DMSO 







Figure 3.3 | Screening of FDA-approved drug and natural compound libraries in 
fluorescence-based DENV NS5 RdRp assay 
Screening results of 640 FDA-approved drugs (a) and 8 natural compounds (b) in 
in vitro NS5 RdRp assay. After pre-incubation of RNA template and GST-NS5 protein, 
drugs or compounds were added to the reaction mixture at a final screening 
concentration of 20 µg/ml in 5% DMSO. BBT-ATP was then added to initiate template 
RNA-dependent de novo RNA polymerization. After an incubation of 2 h at room 
temperature, CIAP was added and further incubated in the dark for 1 h for the liberation 
of BBT from BBT-PPi, a by-product of the incorporation of the nucleotide analogue 
into the growing RNA strand. Liberated BBT was measured by Synergy H1 hybrid 
microplate reader. All readings are expressed relative to 5% DMSO diluent control 
without drugs or compounds. Measurements were taken over 2 independent 
experiments, denoted by red and blue circles.  
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3.4  Summary of primary in vitro NS5 RdRp screening study and in vitro 
validation of hits 
After the completion of the primary screening study, summary statistics were 
consolidated (Figure 3.4a). 
Out of 648 FDA-approved drugs and natural compounds screened against DENV-2 NS5 
RdRp activity, a total of 25 drugs and compounds showed at least a 30% inhibition of 
RdRp activity over two independent experiments. These compounds were grouped into 
6 groups in terms of relative percentage inhibition of RdRp activity compared to the 5% 
DMSO diluent control without drugs or compounds (Figure 3.4a). 
An inclusion criteria set for downstream validation studies was set at a minimal 
inhibition of 50% RdRp activity over two independent experiments in the primary 
screening assay  (Figure 3.4a). Using this criterion, the overall hit rate was 1.2%.  
A total of seven FDA-approved drugs and one natural compound proceeded to the next 
validation step. In descending order of percentage inhibition of RdRp activity, these are: 
Oxiconazole nitrate (compound #507), itraconazole (#469), tolcapone (#136), 
entacapone (#157), butoconazole nitrate (#619), lomofungin (#7), pinacidil (#19) and 
the proanthocyanidin-rich oligomeric polyphenol fraction of the extract from the 
Japanese cinnamon tree (Cinnamomum camphora), kusunoki (#648). 
As the drugs in the FDA-approved drug library were available in limited quantities and 
low concentrations, commercial drugs were purchased for further validation studies. 
Natural compounds were not commercially obtainable. 
These eight drugs and compounds were subjected to the same in vitro NS5 RdRp assay 
conditions to verify their inhibitory activity in varying concentrations (2.5 µM, 25 µM 
and 250 µM for FDA-approved drugs; 0.025 mg/ml, 0.25 mg/ml and 2.5 mg/ml for 
natural compound kusunoki). All drugs and compounds showed a dose-dependent 
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inhibition of in vitro RdRp activity to varying degrees. The least inhibition was detected 





Figure 3.4 | Summary and validation of hit compounds obtained primary screening 
a) Summary statistics of the primary in vitro NS5 RdRp screening study with 
640 FDA-approved drugs and 8 natural compounds. All readings were 
expressed relative to 5% DMSO diluent control without drugs or compounds. A 
total of 25 drugs and compounds showed at least a 30% inhibition of RdRp 
activity over two independent experiments.  
b) Validation experiment of top 8 inhibitors from the primary screening assay. 
The top 8 inhibitors (7 FDA-approved drugs and 1 natural compound) from the 
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primary screening assay showed at least a 50% inhibition of RdRp activity 
relative to 5% DMSO diluent control without drugs or compounds. The 7 drugs 
were obtained commercially, and together with the natural compound, were put 
through the same in vitro NS5 RdRp assay in varying doses (2.5 µM, 25 µM and 
250 µM for drugs obtained commercially; 0.025 mg/ml, 0.25 mg/ml and 2.5 
mg/ml for natural compound kusunoki). All readings were expressed relative to 
5% DMSO diluent control without drugs or compounds. Results are the mean of 




3.5  Secondary screening of top 8 inhibitors in in vitro NS5 RdRp assay using 
RdRp domain mutant protein 
DENV-2 NS5 is a bifunctional protein made up of 2 functional domains: N-terminal 
MTase domain and C-terminal RdRp domain (Ackermann and Padmanabhan, 2001; 
Egloff et al., 2002). The additional validation of the top eight inhibitors in in vitro RdRp 
assay using NS5 RdRp domain mutant (Figure 3.5a) was conducted with two aims: 
1. The RdRp domain mutant protein exhibited in vitro RdRp activity (Figure 3.2c). 
To ensure that the inhibition by drugs seen in the primary screening assay was 
indeed due the action of drugs on RdRp activity of NS5, a RdRp domain mutant 
protein (i.e. lacking MTase domain) was used in the same RdRp assay in an 
attempt to attribute the dose-dependent inhibition of RdRp activity by the drug 
or compound to the RdRp domain specifically. 
 
2. This experiment could give insights into the binding region of the drug to NS5. 
As possible non-nucleoside inhibitors, drugs or compounds could bind in an 
allosteric site either within the RdRp domain, or in a region elsewhere on the 
NS5 protein (eg. MTase domain). Binding to an allosteric site in or outside the 
RdRp could cause a conformational change in the NS5 protein specficially 
within the RdRp active site, affecting RdRp activity (Wang et al., 2003).  
The top eight drugs and compounds were subjected to an in vitro RdRp assay using a 
NS5 RdRp domain mutant (GST-RdRp, Figure 3.5a). Varying concentrations of drugs 
and compounds were applied (2.5 µM, 25 µM and 250 µM for FDA-approved drugs; 
0.025 mg/ml, 0.25 mg/ml and 2.5 mg/ml for natural compound kusunoki). 
All drugs and compounds again showed a dose-dependent inhibition of in vitro RdRp 
activity exhibited by the domain mutant. While most drugs and compounds showed 
similar extents inhibition compared to when full-length NS5 protein was used (Figure 
3.5b), itraconazole exhibited a greater degree of inhibition of RdRp activity when RdRp 
mutant protein was used. This was in contrast to pinacidil and kusunoki, which showed 
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evidence of smaller magnitude of inhibition in the validations assay when RdRp domain 






Figure 3.5 | Validation of top 8 inhibitors in in vitro RdRp assay using NS5 RdRp 
domain mutant 
a) A schematic representation of full-length (GST-NS5) and RdRp domain 
mutant (GST-RdRp) of NS5  
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b) Activity of top 8 inhibitors in in vitro NS5 RdRp assay using RdRp domain 
mutant. The top 8 inhibitors from the primary screening assay showed at least a 
50% inhibition of RdRp activity relative to 5% DMSO diluent control without 
drugs or compounds. These 8 drugs and compounds were subjected to a 
secondary in vitro RdRp assay using GST-RdRp. Varying concentrations of 
drugs and compounds were applied (2.5 µM, 25 µM and 250 µM for FDA-
approved drugs; 0.025 mg/ml, 0.25 mg/ml and 2.5 mg/ml for natural compound 
kusunoki). All readings were expressed relative to 5% DMSO diluent control 
without drugs or compounds. Results are the mean of 3 independent experiments 




3.6  Validation of inhibition of DENV replication by drug/compound in cell-
based system 
The top 8 inhibitors from the in vitro NS5 RdRp assay were next tested in a cell-based 
assay to verify if they had the ability to inhibit DENV replication. This validation step 
comprised of 2 experiments: A cell viability assay to measure the cytotoxicity of a 
drug/compound and a plaque assay to monitor the reduction of viral titer by the 
drug/compound. 
Huh-7.5 cells were seeded in a 96-well plate and infected with DENV-2 at MOI 0.1 
while simultaneously treated with a wide concentration range of drugs/compounds 
diluted in DMEM to a final DMSO concentration of 0.5%. After an incubation of 48 h, 
viral supernatants were collected and the viral titer of each was determined in a plaque 
assay using BHK-21 cells. In parallel experiments, cell viability was analyzed using 
CellTiter-Glo Luminescent Cell Viability Assay reagent (Promega) to measure the 
cytotoxicity of a drug/compound, which measures metabolically active cells through 
quantification of ATP via luciferase activity. 
The values obtained for both cell viability assays (blue) and viral titer (red) 
determination via plaque assays were processed and expressed relative to 0.5% DMSO 
diluent control without drugs or compounds. Results are the mean of 3 independent 
experiments with error bars ± sd. 
 CC50 (concentration of a drug that causes 50% cell death) and EC50 (concentration of a 
drug that inhibits 50% of viral replication) were then calculated from cell viability assay 
and plaque assay data respectively.  
In addition to these values, the selectivity index (SI = CC50/ EC50) of the various drugs 
were derived. As viral titer (and therefore EC50) is affected by both drug/compound 
cytotoxicity and actual inhibition of drug/compound, the selectivity index of an 
effective drug/compound should be greater than 1 to demonstrate that the reduction of 
viral titer is due to the action of a drug/compound inhibiting viral replication. The higher 
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a drug’s SI is, the wider the window is between an effective dose from a cytotoxic dose, 
and hence, the greater its potential as a drug. 
With the exception of oxiconazole nitrate (data not shown), treatment of Huh-7.5 cells 
with the rest of the shortlisted drugs and compounds generally showed a dose-dependent 
decrease in both cell viability and viral titer ( 
Figure a - g). In contrast, oxiconazole nitrate showed significant decrease in neither cell 
viability nor viral titer up to 250 µM. 
 
Figure h shows a summary of the cell-based validation study, together with brief 
additional information known about the drugs. 5 out of 8 drugs (itraconazole, 
entacapone, butoconazole nitrate, pinacidil and kusunoki) and compounds showed an SI 
of higher than 1, showing that 62.5% of the shortlisted drugs and compounds 
demonstrated anti-DENV activity in cultured cells ( 
Figure h).  
A possible inhibitor candidate that may be suitable for future anti-viral use is pinacidil ( 
Figure f). After an initial decrease in cell viability at low concentrations, cell viability 
was still maintained at approximately 80% despite increasing pinacidil concentrations. 
Even though CC50 was not reached, viral titer was almost entirely abolished at 300 µM 
with respect to 0.5% DMSO control. 
Interestingly, of the 5 drugs and compounds that showed anti-DENV activity, the 
proanthocyanidin extract from the Japanese cinnamon tree (Cinnamomum camphora), 
kusunoki ( 
Figure g) reflected the highest SI value of 1387.3 with a non-cytotoxic dose of 145.9 




Due to the high SI recorded, kusunoki was therefore subjected to further experiments to 








Figure 3.6 | Validation of inhibition of DENV replication by drug/compound in 
cell-based infection system 
To measure cytotoxicity of drugs and compounds, Huh-7.5 cells were treated with a 
wide concentration range (indicated in each graph) of drugs/compounds diluted in 
DMEM to a final concentration of 0.5%. A cell viability assay was performed using 
CellTiter-Glo Luminescent Cell Viability Assay reagent (Promega) after 48 h. To 
measure the ability of the drugs/compounds to reduce viral titer, Huh-7.5 cells were 
infected with DENV-2 at MOI 0.1 while simultaneously treated with drugs/compounds. 
Forty-eight hours after infection, viral supernatants were collected and the viral titer of 
each was determined in a plaque assay using BHK-21 cells.   
 
a – g) Cell viability and viral titer measurements after treatment of Huh-7.5 
cells with itraconazole (a), tolcapone (b), entcapone (c), butoconazole nitrate 
(d), lomofungin (e), pinacidil (f) and kusunoki (g), respectively.  Cell viability 
readings expressed relative to 0.5% DMSO diluent control without drugs or 
compounds. Viral titer measurements expressed as PFU/ml. Results are the mean of 





Figure 3.6  | Validation of inhibition of DENV replication by drug/compound in cell-based infection system 
h) Summary of anti-DENV validation in cell-based infection system with additional information on drugs/compounds 
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3.7  Effects of kusunoki in CPE-based anti-dengue assay 
To ensure that kusunoki inhibition of DENV was not a cell-line or assay-specific 
phenomenon, the effects of kusunoki in a CPE-based anti-dengue assay in LLC-MK2 
(monkey kidney) cells were explored. 
This assay was developed based on the CPE of DENV-2 infection seen in LLC-MK2 
cells and anti-dengue activity of a drug/compound is characterized by the rescue of cells 
from infection-induced cell death (Ichiyama et al., 2013). 
In a 96-well plate format, LLC-MK2 cells were treated with range of concentrations of 
kusunoki diluted in EMEM. Following which, half the set of cells were inoculated with 
DENV-2 at MOI 0.5, while the other half remained as a mock infected control. The 
cells were then allowed to proliferate for 5 days. After 5 days of incubation, a MTT 
assay was performed to determine the number of viable cells present (Mosmann, 1983). 
Fluorescence readings were then taken using Infinite® 200 Microplate Reader (Tecan). 
Readings were expressed as a relative percentage of controls, where 100% cell viability 
represented maximum cell growth without infection and kusunoki treatment and 0% cell 
viability represented cell death caused by DENV-2 infection. Results are the mean of 3 
independent experiments with error bars ± sd. 
Kusunoki was found to be similarly non-cytoxtoxic in both LLC-MK2 cells and Huh-
7.5 cells (CC50 in LLC-MK2 cells: 0.183 mg/ml; CC50 in Huh-7.5 cells: 0.202 mg/ml) 
(Figure 3.7,  
Figure g). However, its anti-DENV properties were less apparent in LLC-MK2 cells 
compared to Huh-7.5 cells (EC50 in LLC-MK2 cells: 0.0108 mg/ml; EC50 in Huh-7.5 
cells: 0.000146 mg/ml).  
With a SI of 16.8 in LLC-MK2 cells, the ability of kusunoki to inhibit DENV 





Figure 3.7 | Effects of kusunoki in CPE-based anti-dengue assay 
LLC-MK2 cells treated with range of concentrations of kusunoki diluted in EMEM. 
Following which, half the set of cells were inoculated with DENV-2 at MOI 0.5, while 
the other half remained as a mock infected control. The cells were then allowed to 
proliferate. After 5 days of incubation, a MTT assay was performed to determine the 
number of viable cells present. Fluorescence readings were then taken and expressed as 
a relative percentage of controls, where 100% cell viability represented maximum cell 
growth without infection and kusunoki treatment and 0% cell viability represented cell 
death caused by DENV-2 infection. Results are the mean of 3 independent experiments 




3.8  Inhibitory effect of kusunoki against 4 DENV serotypes 
There are four serologic types of dengue virus, DENV-1 - 4. An ideal property of an 
anti-viral compound for dengue would be the ability to protect the host against all the 4 
serotypes. Thus, the capacity of kusunoki to inhibit the 4 serotypes of DENV was 
examined by plaque reduction assay. 
A suitable non-cytotoxic concentration range of kusunoki in LLC-MK2 cells was first 
determined using results gathered from CPE-based anti-dengue assay (Figure 3.7).  
LLC-MK2 cells were inoculated with 100 PFU of each serotype of DENV, followed by 
0 - 100 µg/ml of kusunoki (final DMSO concentration of 0.5%) diluted in plaque assay 
overlay media. At 5 days post-inoculation, the overlay media was removed and cells 
were washed twice with PBS. This was followed by fixation using 4% 
paraformaldehyde and staining with 1% crystal violet. 
No significant cytotoxic effects were observed with 0 - 100 µg/ml of kusunoki in the 
CPE-based anti-dengue assay (Figure 3.7), indicating that a reduction of plaques was 
solely attributed to the direct anti-DENV action of kusunoki, and not cytotoxicity of the 
compound. Plaques were enumerated (Figure 3.8a) and expressed as a relative 
percentage to the number of plaques produced for incubation with 0.5% DMSO without 
kusunoki (Figure 3.8b). The concentration needed to reduce the number of plaques by 
50%, EC50, was then calculated (Figure 3.8c). 
Kusunoki inhibited DENV in the plaque reduction assays in a dose-dependent manner 
(Figure 3.8a - b). This trend was apparent across all 4 DENV serotypes with comparable 
EC50 values (DENV-1: 32.8 µg/ml; DENV-2: 39.0 µg/ml; DENV-3: 16.5 µg/ml; 






Figure 3.8 | Effect of kusunoki in plaque reduction assay across 4 DENV serotypes 
LLC-MK2 cells were inoculated with 100 PFU of each serotype of DENV, followed by 
0 – 100 µg/ml of kusunoki (final DMSO concentration of 0.5%) diluted in plaque assay 
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overlay media. At 5 days post-inoculation, the overlay media was removed and cells 
were washed twice with PBS. This was followed by fixation using paraformaldehyde 
and staining with crystal violet. After a further washing step and drying of plates, 
number of plaques were enumerated. These were expressed as a relative percentage to 
the number of plaques produced for incubation with 0.5% DMSO without kusunoki. 
a) Representative plaque reduction assay for enumeration. Plaque reduction 
assay plate image from infection with DENV-2 and simultaneous treatment with 
0 - 100 µg/ml kusunoki. 
b) Plaque reduction assay results. Plaque reduction assay results from infection 
with 4 DENV serotypes respectively, with simultaneous treatment with 0 – 100 
µg/ml kusunoki. (DENV-1: blue, DENV-2: red, DENV-3: green, DENV-4: 
purple). Plaques enumerated expressed as a relative percentage to the number of 
plaques produced for incubation with 0.5% DMSO without kusunoki. 




3.9  Mechanistic inhibitory action of kusunoki 
To give mechanistic insights into the anti-DENV action of kusunoki, a time of addition 
assay was first performed. This assay broadly dichotomizes inhibitors by distinguishing 
their mode of action, differentiating attachment/entry inhibitors from intracellular 
inhibitors that work against any other step in the rest of the viral replication cycle, by 
adding the inhibitor in question at different time points before and after viral inoculation 
and examining the extent of viral inhibition. 
Twenty-four hours after seeding of LLC-MK2 cells, 100 PFU of DENV-2 was 
inoculated at 4°C for 1.5 h. After washing with PBS, the plates were shifted for 
culturing in a 37°C incubator. Kusunoki (50 µg/mg) diluted in plaque assay overlay 
medium (0.8% methylcellulose, 10% FBS and antibiotics in EMEM) was added to the 
cells at different time points pre- and post-infection (-1.5, 0, 1, 2, 3, 4 and 5 h). Heparin 
(100 µg/mg), a known DENV entry inhibitor, was used as a positive control, while 
DMSO was used as a negative control. After 5 days, cells were fixed and stained. 
Plaques were then enumerated. 
Supporting its role as a RdRp inhibitor discovered by the in vitro RdRp assay (Figure 
3.4b, Figure 3.5b), viral inhibition was apparent in early stages of the infection (Figure 
3.9a, >1 h post infection), at time points consistent with steps in the viral replication 
cycle which occur intracellularly after entry and internalization of the viral particle 
(Wang et al., 2011b).  
Next, to further support the hypothesis that kusunoki is a possible RdRp inhibitor, a 
DENV subgenomic RNA replicon system containing the NS genes was used. Twenty-
four hours after BHK-21 cells containing a DENV replicon with a luciferase reporter 
gene were seeded, the cells were treated with kusunoki (40 µg/ml) diluted in DMEM. 
NITD-008 (10, 20, 50 µg/ml), a known DENV RdRp inhibitor, was used as a positive 
control. After an incubation of 48 h, the cells were harvested and lysed. The cell lysate 
was then subjected to luciferase assay. 
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At a low concentration of 40 µg/ml, kusunoki was sufficient to reduce luciferase activity 
by 50% (Figure 3.9b), consistent with its ability to inhibit RdRp activity (Figure 3.4b). 
Surprisingly, a higher degree of viral inhibition was evident when kusunoki was added 
at even earlier time points (-1.5 to 1 h) post infection in the time of addition assay 
(Figure 3.9a). The inhibitory profile of kusunoki at these time points was found to be 
similar to that of heparin, a known DENV entry inhibitor (Figure 3.9a). This suggests 
that although kusunoki can inhibit intracellular viral RNA replication, it also inhibits 
attachment/entry of DENV. 
In an attempt to clarify if kusunoki inhibits DENV at either the viral attachment or 
internalization step, a binding assay was performed. This assay is based on early 
findings that distinguished both processes. While viral attachment is a temperature-
independent process which occurs at both 4 and 37°C, viral internalization can only 
proceed at 37°C (Salas-Benito and del Angel, 1997). 
LLC-MK2 cells were inoculated with 200 PFU of DENV-2 at 4°C or 37°C for 1.5 h in 
the presence of kusunoki (50 µg/mg) or DMSO (negative control). After the cells were 
washed with PBS, plaque assay overlay medium (0.8% methylcellulose, 10% FBS and 
antibiotics in EMEM) was added to the wells. After 5 days, cells were fixed and stained. 
Plaques were then enumerated. 
Ninety-eight percent viral inhibition was attained at 4°C, while a comparable 100% 
inhibition was achieved at 37°C (Figure 3.9c). This suggests that kusunoki possibly 
inhibits DENV attachment to cells. 
In conclusion, kusunoki seems to inhibit DENV at multiple stages of its replication 





Figure 3.9 | Mechanistic inhibitory action of kusunoki 
a) Time of addition assay 
Twenty-four hours after LLC-MK2 cells were seeded, 100 PFU of DENV-2 was 
 84 
 
inoculated at 4°C for 1.5 h. After the cells were washed with PBS, the plates 
were shifted for culturing in a 37°C incubator. Kusunoki (50 µg/mg) diluted in 
plaque assay overlay medium (0.8% methylcellulose, 10% FBS and antibiotics 
in EMEM) was added to the cells at different time points pre- and post-infection 
(-1.5, 0, 1, 2, 3, 4 and 5 h). Heparin (100 µg/mg), a known entry inhibitor of 
DENV, was used as a positive control, while DMSO was used as a negative 
control. After 5 days, cells were fixed and stained. Plaques were then 
enumerated. Number of plaques attained with respective compound treatments 
was expressed relative to the number of plaques for DMSO, and finally 
expressed as percentage inhibition.  
b) DENV replicon luciferase assay 
Twenty-four hours after BHK-21 cells containing a DENV subgenomic replicon 
with a luciferase reporter were seeded, the cells were treated with kusunoki (40 
µg/ml) diluted in DMEM. NITD-008 (10, 20, 50 µg/ml), a known DENV RdRp 
inhibitor, was used as a positive control. After an incubation of 48 h, the cells 
were harvested and lysed. The cell lysate was then subjected to luciferase assay. 
Luminescence intensity is expressed relative to 0.5% DMSO control without 
kusunoki. 
c) Binding assay 
Twenty-four hours after LLC-MK2 cells were seeded, 200 PFU of DENV-2 was 
inoculated at 4°C or 37°C for 1.5 h in the presence of kusunoki (50 µg/mg) or 
DMSO (negative control). After the cells were washed with PBS, plaque assay 
overlay medium (0.8% methylcellulose, 10% FBS and antibiotics in EMEM) 
was added to the wells. After 5 days, cells were fixed and stained. Plaques were 
then enumerated. Plaques enumerated are expressed as a relative percentage to 
the number of plaques produced for incubation with 0.5% DMSO without 





Chapter 4. Discussion 
The aims of the present project may be divided into three broad categories: 
1. Synthesis of high quality DENV-2 NS5 full-length and RdRp domain mutant 
proteins by utilizing the wheat germ cell-free protein synthesis system 
2. Application of these proteins in a fluorescence-based in vitro NS5 RdRp 
screening assay  
3. Identification of inhibitors against DENV NS5 by screening libraries of FDA-
approved drugs and natural compounds using the in vitro NS5 RdRp assay 
Conceptually, this is the first report to exploit the wheat germ cell-free protein synthesis 
system for an in vitro NS5 RdRp assay to our knowledge. Through conducting these 
studies, some candidate drugs/compounds were obtained and additionally validated in 
the primary and secondary in vitro screening assays respectively. Their inhibitory effect 
was further evaluated in a cell-based DENV infection system by exploring their 
cytotoxicity and capacity to reduce viral titers. Investigations to reveal the extent and 
mechanistic details of inhibition of the best candidate were then carried out.  
4.1  Production of NS5 protein using wheat germ cell free system 
DENV NS5 proteins used in in vitro assays have traditionally been produced by E. coli 
and baculovirus-infected insect cell-based systems (Niyomrattanakit et al., 2010; Tan et 
al., 1996). Although NS5 proteins yielded from the both system have been shown to 
have RdRp activity, they have many shortcomings. 
For instance, although the E. coli system produces a high yield of proteins rapidly at a 
low cost, a major inherent weakness of it is the lack of post translational modifications 
present due its nature of being a prokaryotic-based system. Conversely, although a 
euykaryotic baculovirus system allows for some degree of post-translational 
modifications, it is both an expensive and time-consuming protein synthesis process of 
 86 
 
up to 10 days. Furthermore, being a cell-based technique, it may be highly susceptible 
to contamination. 
In recent years, an increasing number of post translational modifications have been 
discovered for DENV NS5. These include phosphorylation, myristoylation, 
glycosylation and amidation (Khan et al., 2008). With some of these ascertained to be 
important for its function, such as in the study by Bhattacharya et. al. that uncovered 
that the phosphorylation of NS5 at amino acid residue 449 modulates DENV 
replication, there is a pressing need to seek out an alternative NS5 protein synthesis 
system (Bhattacharya et al., 2009). 
In this study, eukaryotic wheat germ cell-free protein synthesis system was employed to 
produce DENV NS5 protein. Being a eukaryotic system, the wheat germ system has 
also been shown to allow post-translational modifications such as glycosylation, 
acetylation, phosphorylation, iso-prenylation, myristoylation, complex protein folding 
and proteolytic processing (Martin et al., 1997; Nakamura, 1993; Rubenstein and 
Chappell, 1983; Zagorski et al., 1983). This ability would enable recombinant NS5 
synthesized to be a more physiologically relevant protein. 
Despite being a fairly new system, this protein production system is well-established, 
having generated 13,364 human proteins (encompassing 70% of the 22,000 human 
genes). Additionally, 77% of the phosphatases synthesized by this system have also 
showed biological activity (Goshima et al., 2008). 
In addition to high quality functional proteins, the wheat germ cell-free protein 
synthesis system is also rapid, taking only one day to produce a large and consistent 
yield of proteins in a cost-efficient manner. 
The wheat germ cell free system was successfully utilized to synthesis full-length NS5, 
RdRp domain mutant and DHFR proteins, all which were fused with N-terminal GST-
tag for affinity purification. A representative CBB staining of GST-NS5 samples from 
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the various purification steps is shown (Figure 3.1b). In the crude protein sample after in 
vitro translation (Lane 2, Figure 3.1b), a protein band of the correct size (133 kDa) was 
seen, showing that protein production was a success. Importantly, proteins produced 
were also soluble, an advantage over the use of the E. coli system as it is known to 
result in the accumulation of misfolded heterogenous proteins into insoluble aggregates 
which are biologically non-functional (Ventura, 2005).  
After successive purification steps of high efficiency, GST-NS5 was further subjected to 
buffer exchange chromatography as the presence of reduced glutathione could 
potentially affect downstream assays. This process did not affect the purity of the 
sample, as seen in the single band in the final preparation (Figure 3.1b, lane 5). In 
addition, western blotting analysis also showed specificity of the NS5 protein produced 
(Figure 3.1c, lane 1). 
In addition, the full-length and RdRp domain mutant proteins of NS5 also demonstrated 
RNA polymerization activity in vitro (Figure 3.2c), lending credibility to the study’s 
proposition of NS5 synthesized using the eukaryotic wheat germ cell-free protein 
synthesis system as a viable alternative to other present protein synthesis methods that 
balances cost, efficiency and physiological relevance. 
4.2  Development of fluorescence-based NS5 RdRp assay using wheat germ 
cell-free system-produced NS5 proteins 
Following the increasing recognition of DENV NS5 RdRp as a promising drug target, a 
wide myriad of RdRp enzymatic assays in a cell-free setting have been developed, most 
of which utilize radioactive labels to track the incorporation of nucleotides. A popular 
radioactive assay format is SPA, which is based on the quantification of radioactivity 
present on newly transcribed RNA incorporated with radioactive nucleotides (Yap et al., 
2007). 
Although these radioactivity-based assays are still widely used, there has been a 
growing inclination to move away from the use of radioactive labels. The motivation 
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behind this shift is that radioactive assays for use in high-throughput screening studies 
have the aptitude to produce large amounts of waste that can cause health and safety 
concerns. In addition, both the acquirement and disposal of these reagents are costly 
(Seethala and Fernandes, 2001). 
A solution to this is the use of fluorophore-conjugated nucleotides as a substitute to 
radioactive-labeled nucleotides. An example of this is BBT-ATP (Niyomrattanakit et 
al., 2011). Fluorescence readings can then be taken after nucleotide incorporation which 
in turn results in the release of fluorophore tags. These measurements would therefore 
be proportional to NS5 RdRp activity. 
To clarify the specificity of the fluorescence-based NS5 RdRp assay constituents, core 
assay constituents were removed separately. This included reactions with no proteins 
(protein buffer was added in place of GST-NS5), no RdRp cofactor MnCl2 and no 
nucleotide analogue BBT-ATP respectively (Figure 3.2a). These were then compared to 
the reaction with the full reagent mix. Both the no protein and no BBT-ATP reactions 
display an acceptable minimal background RdRp activity at approximately 10% and 1% 
respectively. Without the cofactor of RdRp, MnCl2, NS5 RdRp activity was decreased 
to about 40%. While the divalent metal ion greatly enhances RdRp activity as a 
cofactor, it does not seem to be obligatory for the reaction to occur. This observation has 
also been reported with the HCV RdRp, NS5B (Ranjith-Kumar et al., 2004). In 
addition, a recently reported DENV RdRp inhibitor, NITD-008 (Yin et al., 2009), also 
inhibited approximately 40% of NS5 RdRp activity at 50 µM, lending weight to the 
functionality of the enzyme assay. 
The measured fluorescence levels in the in vitro RNA polymerization assay correlated 
to RdRp activity specific to NS5 protein, as a dose-dependent increase in fluorescence 
intensity was also observed with the increase of NS5 (Figure 3.2b). 
The relative RdRp activities of DENV-2 full-length NS5, its RdRp mutant protein and 
an unrelated protein, DHFR, which was used as a negative protein control, were 
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explored (Figure 3.2c). As expected, DHFR only produced background fluorescence 
levels of about 10%, which was comparable to the no protein control.  
Although equal concentrations of full-length NS5 and RdRp domain mutant proteins 
were used, the RdRp domain mutant protein only achieved approximately 80% of RNA 
polymerization activity compared to full-length NS5 (Figure 3.2c). The results attained 
in this study raise the possibility of the MTase domain contributing to RdRp activity of 
NS5. Interaction between the two functional domains MTase and RdRp is currently 
unknown as the DENV NS5 protein crystal structure has not been solved in its entirety. 
While some reports suggest that these domains are independent and functionally 
irrelevant to each other (Bussetta and Choi, 2012), the results in this study seem to 
suggest otherwise. This notion is echoed in other reports which show genetic evidence 
of crosstalk between both domains (Malet et al., 2007). More recently, interaction 
between both domains (amino acid residues 46-49 in the MTase αA3-motif and residue 
512 in RdRp) were confirmed using pull-down assays and mutagenesis studies of these 
interacting regions have been found to completely abolish DENV viability (Tan et al., 
2013). 
4.3  Screening libraries of FDA-approved drugs and natural compounds 
Productivity has not kept pace with increasing R&D investments in the pharmaceutical 
industry. Despite exponential increase in R&D costs over the decades, a proportional 
increase in approved drugs has not been met. This increase in R&D costs has been 
further exacerbated by the high attrition rates of drugs from clinical trials, dubbed “the 
clinical trial cliff”, with the number of drugs terminated in Phase III of clinical 
development doubling in 5 years, reaching 55 compounds in a 2 year period of 2008 - 
2010 (CMR, 2012). The primary reason for drop-outs in Phase I and II is safety-related 
issues, while withdrawals in Phase III are ascribed to a lack of efficacy (Novac, 2013). 
To combat these problems, the idea of recycling late-phase-failed compounds or already 
marketed drugs to a new indication was sprung. The process of identifying or 
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developing new uses for existing or abandoned drugs or compounds is called “drug 
repositioning” (Ashburn and Thor, 2004). This is an appealing prospect from various 
standpoints. 
Firstly, from the industrial standpoint, this course of action can potentially bring in more 
revenue to maximize R&D expenditure. Also, proven formulation and manufacturing 
routes can further reduce additional related investment expenses. 
From an ethical stance, the information generated by existing patient data in clinical 
trials for future indications should be capitalized on to its full potential. 
Lastly, from the scientific perspective, compounds with established safety and 
bioavailability profiles would undoubtedly get a good head-start in the R&D process. 
These can probably enter clinical trials quicker than NMEs and would less likely fail 
due to human safety and pharmacokinetic issues (Stuart-Kregor, 2007). In addition, a 
well-characterized pharmacology could aid studies into the mechanistic analysis of new 
indications.  
The success stories of several repositioned drugs such as sildenafil (angina to erectile 
dysfunction) and thalidomide (morning sickness to multiple myeloma) have been well 
chronicled (Novac, 2013). More recently, mifepristone, initially approved as an 
abortifacient, has also been repurposed as treatment for Cushing’s syndrome in early 
2012 (Castinetti et al., 2012). These case studies are indicative of the recognition of the 
increasing importance of drug repositioning today.  
Brought into the context of this study, these principles were a guide into the selection of 
screening library to utilize. For the various reasons aforementioned, a library of FDA-
approved drugs was opted for. In addition, to further expand this screening library, 
natural compounds, some of which are used as health supplements, were also appended. 
Natural compounds, often used in traditional medicine, were chosen for their better 
safety and tolerance profiles compared to synthetic compounds or general NMEs 
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(Patwardhan and Vaidya, 2010). This is probably the reason why over 60% of anti-
cancer and 75% of anti-infective drugs approved from 1981 - 2002 can be traced back to 
natural origins (Gupta et al., 2005). 
The screening of FDA-approved drugs and natural compounds in an in vitro assay 
presents as a safer starting point. FDA-approved drugs, for example, would have passed 
all in vivo toxicity testing successfully. The choice of using safe drugs and compounds 
for screening would ideally accelerate the follow-up cell-based evaluation and drug 
repositioning process significantly, and is thus the approach taken in this study.  
The importance of this sentiment has been echoed in recent efforts. Much of anti-
dengue drug discovery still remains in its infant stages of identification potential 
antiviral candidates. A large proportion of anti-dengue drug discovery has been led by 
Novartis Institute for Tropical Diseases and that has led to the development of many 
high throughput assays to screen their library of 1.8 million compounds. The most 
promising NS5 RdRp inhibitors (NITD-008, NITD-449 and NITD-203) were found to 
have high inhibitory effects and low cytoxicity in vitro. However, all exhibited high 
toxicity in in vivo studies and advancement to drug development were halted (Chen et 
al., 2010; Yin et al., 2009), further lending weight to the approach of this study to screen 
libraries of FDA-approved drugs and natural compounds as a safer alternative. 
4.4  Primary screening of libraries of FDA-approved drugs and natural 
compounds in in vitro NS5 RdRp assay 
After the fluorescence-based NS5 RdRp assay using DENV-2 NS5 synthesized by 
wheat germ cell free system was established, the primary screening of a total of 648 
drugs and compounds from libraries of FDA-approved drugs (Figure 3.3a) and natural 
compounds (Figure 3.3b) was conducted.  
Polymerase inhibitors against RNA viruses developed to date fall into two categories: 
nucleoside inhibitors and non-nucleoside inhibitors. Nucleotide analogues are 
administered as pro-drugs for increased safety, bioavailability and efficacy (Peterson 
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and McKenna, 2009). Since they are nucleotide analogues, these have to be successively 
phosphorylated by cellular enzymes such as phosphoglycerate kinase and creatine 
kinase (Cihlar and Ray, 2010). These are structurally similar to nucleosides and they 
work as antimetabolites by being incorporated into growing RNA strands. Unlike actual 
nucleotides, nucleotide analogues lack a 3´-hydroxyl group on the deoxyribose moiety, 
which is usually hydrolyzed to form a phosphodiester bond with the next nucleic acid. 
These nucleoside analogues thereby act as chain terminators. 
Non-nucleoside inhibitors, on the other hand, may not necessarily bear a structural 
resemblance to nucleotides. An HCV study has revealed that by binding to allosteric 
sites of the NS5B protein, these inhibitors change the conformation of the active site 
such that the NS5B is no longer competent to carry out its RdRp activities (Wang et al., 
2003). 
As majority of the drugs and compounds screened belonged to the FDA-approved 
library, any inhibitors picked up by the assay were more likely to be non-nucleoside 
inhibitors. This is because any FDA-approved nucleoside inhibitors would be pro-drugs, 
and would not have been able to be converted to an active triphosphate nucleotide form 
in an in vitro setting. A limitation in using a FDA-approved library of drugs in an in 
vitro assay would therefore be the inevitable inability to identify hits that are 
administered as pro-drugs (e.g. nucleoside analogues) as they require processing in vivo. 
This shortcoming, however, may be seen as a better alignment towards the search for 
safe anti-dengue drugs as mitochondrial toxicity and other adverse events have been 
reported as a common side effects of the usage of nucleotide analogues, due to structural 
similarities to endogenous nucleotides as well as differential tissue-specific levels of 
pro-drug activation (Lund et al., 2007; Noble et al., 2010). 
Out of 648 FDA-approved drugs and natural compounds screened against DENV-2 NS5 
RdRp activity, a total of 20 drugs and five natural compounds showed at least a 30% 
inhibition of RdRp activity over two independent experiments (Figure 3.4a). 
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Two interesting trends were noted. Of the 20 top drug inhibitors, 6 were azole anti-
fungal drugs (compounds #507, #469, #619, #490, #376 and #565). This class of anti-
fungal drugs inhibits the enzyme lanosterol 14-α-demethylase which is the enzyme 
necessary to convert lanosterol to ergosterol. This is turn results in the depletion of 
ergosterol in fungal membranes, disrupting its structure and function that leads to the 
eventual inhibition of fungal growth. This could imply a possible structural similarity 
between DENV RdRp and the region where these drugs bind to lanosterol 14-α-
demethylase. If proven to be effective RdRp inhibitors, this can potentially impact 
endeavours in rational drug design as attempts so far have been hampered due to the 
lack of extensive knowledge of the entire NS5 protein structure (Ditursi et al., 2006). 
Another fascinating observation was that five (#136, #157, #473, #485, #94) out of the 
top 20 drug inhibitors were used for the treatment of Parkinson’s disease. This 
degenerative disorder of the central nervous system is caused by the death of dopamine-
generating cells in the substantia nigra of the brain. Levodopa, a precursor of dopamine, 
is usually administered to relief disease symptoms. In addition, this is usually coupled to 
a dopa decarboxylase inhibitor and catechol-O-methyl transferase (COMT) inhibitor to 
decrease side effects and increase bioavailability of levadopa (Kaakkola, 2000). This 
combination of three classes of drugs is commercially available as a “triple therapy in a 
pill” such as Stalevo (levodopa/entacapone/carbidopa). As levodopa (#473)  and 
entacapone (#157, COMT inhibitor), together with another dopa decarxylase inhibitor, 
benserazide (#233), were all found to independently inhibit RdRp activity in the 
primary screen, the potential of using anti-parkinsonian dopaminergic combination 
medication such as Stalevo as an antiviral drug against DENV could bring about 
synergistic effects and seems promising and worthy of further exploration. 
An inclusion criteria set for downstream validation studies was set at a minimal 
inhibition of 50% RdRp activity over two independent experiments in the primary 
screening assay (Figure 3.4a). Using this criterion, the overall hit rate was 1.2%. In 
comparison to other high-throughput screening assays to identify RdRp inhibitors that 
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typically use a 25% - 50% RdRp activity inhibition cut-off to yield hit rates ranging 
from 0.001% to 0.7%, the conservative criterion of 50% used in this study has a 
significantly higher hit rate, suggesting that the approach taken by the study in terms of 
choice of screening libraries could be a more efficient way to identify DENV NS5 
RdRp inhibitors (Niyomrattanakit et al., 2011; Niyomrattanakit et al., 2010; Wang et al., 
2011a). 
A total of 7 FDA-approved drugs and 1 natural compound proceeded to the next 
validation step. In descending order of percentage inhibition of RdRp activity, these are: 
oxiconazole nitrate (compound #507), itraconazole (#469), tolcapone (#136), 
entacapone (#157), butoconazole nitrate (#619), lomofungin (#7), pinacidil (#19) and 
the proanthocyanidin-rich oligomeric polyphenol fraction of the extract from the 
Japanese cinnamon tree (Cinnamomum camphora), kusunoki (#648). As the drugs in 
the FDA-approved drug library were available in limited quantities and low 
concentrations, commercial drugs were purchased for further validation studies. Natural 
compounds were not commercially obtainable. 
These eight drugs and compounds were subjected in varying concentrations to the same 
primary in vitro NS5 RdRp assay conditions once again for verification. All drugs and 
compounds showed a dose-dependent inhibition of in vitro RdRp activity to varying 
degrees (Figure 3.4b), corroborating the data from the primary screen. 
4.5  Secondary screening of libraries of FDA-approved drugs and natural 
compounds with RdRp domain mutant 
DENV-2 NS5 is a bifunctional protein made up of N-terminal MTase domain and C-
terminal RdRp domain (Ackermann and Padmanabhan, 2001; Egloff et al., 2002).  
The secondary screening of the top eight inhibitors from the in vitro NS5 RdRp assay 
using RdRp domain mutant (Figure 3.5b) was conducted with following two aims. 
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Firstly, the RdRp domain mutant was shown to demonstrate RNA polymerization 
activity (Figure 3.2c). To ensure that the inhibition by compounds seen in the primary 
screening assay was indeed due the action of the compounds on RdRp region of NS5, 
the RdRp domain mutant was used in the same assay in place of full-length NS5 protein 
in an attempt to attribute the dose-dependent inhibition of RNA polymerization activity 
by the drug or compound to the RdRp domain specifically. 
Secondly, this experiment could also give insights into the binding region of the drug to 
NS5. As possible non-nucleotide analogue inhibitors, drugs or compounds could bind in 
an allosteric site either within the RdRp domain, or in a region elsewhere on the NS5 
protein (eg. MTase domain). Binding to an allosteric site in or outside the RdRp could 
cause a conformational change in the NS5 protein specficially within the RdRp active 
site, affecting RdRp activity (Wang et al., 2003).  
All drugs and compounds showed a dose-dependent inhibition of in vitro activity of the 
RdRp domain mutant. Most drugs and compounds showed similar extents inhibition 
compared to when full-length NS5 protein was used (Figure 3.5b), suggesting that they 
bind to a region within the RdRp domain, directly interfering with enzymatic activity of 
NS5.  
Conversely, itraconazole exhibited a greater degree of inhibition of RdRp activity when 
the RdRp mutant was used instead of wild type NS5, while in contrast, pinacidil and 
kusunoki showed evidence of smaller magnitude of inhibition in the secondary 
screening assay (Figure 3.4b and 3.5b). These may be indicative that itraconazole, 
pinacidil and kusunoki bind to multiple sites within NS5, with the major inhibitory site 
of itraconazole being within the RdRp domain and those of pinacidil and kusunoki 
being outside this domain. In addition, differences in inhibitory effects of compounds 
when wild type NS5 and domain mutant are used are also consistent with data shown 
earlier (Figure 3.2c) that suggests interaction between the MTase (or elsewhere on NS5) 
and RdRp domains, a phenomenon supported by other recent studies (Malet et al., 2007; 
Tan et al., 2013). This possible interaction seems to affect RdRp activity.  
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4.6  Validation of inhibition of DENV replication by drug/compound in cell-
based system 
The top eight inhibitors from the in vitro RdRp assay of NS5 were next tested in a cell-
based assay to verify if they had the ability to inhibit DENV replication. This validation 
step comprised of 2 experiments: A cell viability assay to measure the cytotoxicity of a 
drug/compound and a plaque assay to monitor the reduction of viral titer by the 
drug/compound. CC50  and EC50  were then calculated from cell viability assay and 
plaque assay data respectively.  
In addition to these values, the selectivity index (SI = CC50/ EC50) of the various drugs 
were derived. As viral titer (i.e. EC50) is a combined consequence by both 
drug/compound cytotoxicity and actual inhibition of drug/compound, the selectivity 
index of an effective drug/compound should be greater than 1 to demonstrate that the 
action of a drug/compound inhibiting viral replication plays a more major role in the 
contribution to viral titer reduction. The higher a drug’s SI is, the wider the window is 
between an effective dose from a cytotoxic dose, and hence, the greater its potential as a 
drug. 
With the exception of oxiconazole nitrate (data not shown), treatment of Huh-7.5 cells 
with the rest of the shortlisted drugs and compounds generally showed a dose-dependent 
decrease in both cell viability and viral titer ( 
Figure a - g). In contrast, oxiconazole nitrate showed significant decrease in neither cell 
viability nor viral titer up to 250 µM. 
 
Figure h shows a summary of the cell-based validation study, together with brief 
additional information known about the drugs. Five out of 8 shortlisted 
drugs/compounds (itraconazole, entacapone, butoconazole nitrate, pinacidil and 
kusunoki) showed an SI of higher than 1, showing that 62.5% of the shortlisted drugs 
and compounds demonstrated anti-DENV activity in cultured cells ( 






The discrepancy between the effectiveness of the compounds inhibiting RdRp activity 
in the RdRp enzymatic assay and the low potency of DENV inhibition in cell-based 
assays is apparent through the higher doses of drugs needed in cell-based assays to exert 
an antiviral effect. This may be attributed to two main reasons.  
1. As metabolism of majority of the shortlisted drugs occur primarily in the liver, 
the use of human liver cells (i.e. Huh-7.5) for cell-based testing could have 
resulted in the rapid breakdown of the active drug. This would have lowered the 
effective drug concentration during cell-based antiviral screening, and 
consequently, concentrations of drug to achieve an antiviral effect could not be 
reached. This is held in contrast to enzymatic assays where the drugs would not 
be broken down quickly. To combat this, the use of a non-liver DENV-relevant 
cell line could have been used for testing to lengthen the half-life of the drugs. 
Additionally, additional dosing to maintain the effective drug concentration in 
the culture media could also be considered. 
2. The indications these drugs were approved for by the FDA were not for the 
treatment of DENV infection. As such, doses that achieve antiviral effects in 
cell-based assays may be much higher than that of approved doses for their 
original indications. This could translate to toxicity of the drugs when used at 
high concentrations in cell-based assays, lowering drug potency significantly. A 
possible strategy to counteract this is the chemical modification of the shortlisted 
drugs to mediate better interaction with binding sites on DENV NS5 RdRp to 
disrupt its activity. 
Itraconazole and butoconazole nitrate, two of the five validated hits, are both azole anti-
fungal drugs, as previously mentioned in Section 4.4 The inhibitory action of azoles 
against DENV in Vero cells has previously been reported (Barradas et al., 2008; 
McDowell et al., 2010), and may be regarded as an independent validation of this 
study’s results. In addition, one of these azole compounds, ETAR, has also been shown 
to exhibit antiviral efficacy against a range of flaviviruses in vitro (McDowell et al., 
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2010), raising the possibility that these azole drugs could perform well as broad-
spectrum inhibitors. This could also suggest that the binding site of these azole anti-
fungal drugs to NS5 lie in one or more of the 13 highly conserved sequences of DENV 
NS5 which is also found in 64 other flaviviruses (Khan et al., 2008). 
A possible inhibitor candidate that may be suitable for future antiviral use is pinacidil ( 
Figure f). Pinacidil is an anti-hypertensive drug that was approved for clinical use by 
FDA in 1989. A cyanoguanidine drug that opens ATP-sensitive potassium channels, the 
administration of this drug results in the relaxation of vascular smooth muscle to 
produce peripheral vasodilatation and hence, a consequent reduction in blood pressure 
(Friedel and Brogden, 1990; Gollasch et al., 1995). After an initial decrease in cell 
viability at low concentrations, cell viability was maintained at approximately 80% 
despite increasing pinacidil concentrations. Even though CC50 was not reached, viral 
titer was almost entirely abolished at 300 µM with respect to 0.5% DMSO diluent 
control.  
This could possibly pose as a challenge as the concentration of 300 µM of pinacidil 
would be unattainable in vivo by the current standard clinical dose of the drug used for 
anti-hypertensive purposes. Illustrated in the study by Thuillex et al. which 
administered a standard dose of 25 mg of pinacidil to healthy volunteers, the peak 
plasma concentration of pinacidil was approximately 60 ng/ml (0.25 µM) 2 hours after 
oral administration (Thuillez et al., 1991). Although this big difference in drug 
concentration might seem daunting, a 2-pronged approach may be taken to overcome 
this. Firstly, it is important to realize that it is not necessary for a drug to fully eradicate 
viremia. For example, it has been suggested that a mere 50% inhibition of viral 
replication could be sufficient enough to bring the viral load down to a controllable 
level for subsequent host immune system clearance (Botting and Kuhn, 2012). Hence, a 
much lower concentration of pinacidil could be sufficient for an antiviral effect in an 
immune competent in vivo system compared to an in vitro cell culture system as 
employed in this study.  Secondly, plasma concentration of pinacidil may also be 
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increased as no adverse effects have been observed for up to 300 ng/ml in healthy 
volunteers (Ward et al., 1984). The plasma concentration may be further elevated by (i) 
Increasing the standard dose of 25 mg: this may be adjusted upwards to 0.535 mg/kg 
(DIS, 2012); (ii) Utilizing intravenous delivery of drug instead of oral administration as 
this has been known to increase the plasma concentration of pinacidil by at least 5 times 
(McBurney et al., 1985).  With these strategies, pinacidil would make a feasible 
inhibitor against DENV for further in vivo testing. 
Interestingly, of the five drugs and compounds that showed anti-DENV activity, the 
proanthocyanidin-rich oligomeric polyphenol extract from the Japanese cinnamon tree 
(Cinnamomum camphora), kusunoki ( 
Figure g), reflected the highest SI value of 1387.3 with a non-cytotoxic dose of 145.9 
ng/ml needed to reduce viral titer by 50%, suggesting a wide window for therapeutic 
anti-DENV use. 
The antiviral property of cinnamon is not surprising. Cinnamon, a spice obtained from 
the inner bark of several trees from the genus Cinnamomum, has traditionally been used 
in traditional medicine for a myriad of aliments. The most commonly studied cinnamon 
plant species include C. verum, C. zeylanicum and C. cassia. Antiviral effects of many 
cinnamon-derived compounds have already been discovered. In an in vitro screening 
study using an assortment of plants utilized in traditional Indian medicine, a C. cassia 
extract was shown to have an inhibitory effect on HIV (Premanathan et al., 2000). In the 
same year, yet another group reported the in vitro and in vivo anti-herpes ability of 
eugenol, a compound commonly found in essential oils distilled from cinnamon 
(Benencia and Courreges, 2000). More recently, the compound cinnzeyanine attained 
from C. zeylanicum, was revealed to have antiviral properties in a silkworm baculovirus 
model. Cinnezeylanine was then later confirmed to have inhibitory effects on the 
proliferation of HSV in cultured Vero cells (Orihara et al., 2008). 
The kusunoki extract used in the study was a polyphenol-enriched extract rich in 
oligomeric proanthocyanidins (PAs). The positive health effects associated with the 
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intake of cinnamon have been partially attributed to its phenolic composition of PAs. 
PAs are a class of polyphenolic compounds often found in various species of plants. 
These are oligomers of flavan-3-ol monomer units. The most common monomeric units 
consist of the classes procyanidins (chains of catechin, epicatechin, as well as their 
gallic acid esters) and prodelphinidins (gallocatechin, epigallocatechin, and their 
galloylated derivatives) (Lazarus et al., 1999). Indeed, mass spectroscopy techniques in 
recent studies have revealed that PAs derived from cinnamon bark include combinations 
of (epi)catechin, (epi)catechingallate, (epi)gallocatechin, and (epi)afzelechin (Mateos-
Martin et al., 2012). In addition to their cardioprotective, anti-tumor, anti-inflammatory, 
anti-carcinogenic and anti-allergic activities, PAs have also been known to possess 
antiviral activity (Frankel, 1995; Gescher et al., 2011a; Leung et al., 2001). These 
include viral inactivation against feline calicivirus, which are experimental surrogates 
for noroviruses, and coxsackievirus, which was used as a representative enteric virus 
(Iwasawa et al., 2009). In addition, in vitro antiviral activity against HSV has also been 
uncovered (Xu et al., 2010). More recently, the anti-HSV activity by PAs has been 
elucidated to be by the inhibition of viral adsorption and penetration (Gescher et al., 
2011b). 
Due to the high SI recorded, kusunoki was therefore subjected to further experiments to 
validate its potential as an anti-viral therapeutic. 
4.7  Effects of kusunoki in CPE-based anti-dengue assay 
Antiviral activities of compounds have a possibility to occur in a cell-line or assay-
specific dependent manner. As sound and reproducible in vitro studies form the premise 
and foundation of further studies, this has dire implications on the ultimate goal of 
translational studies to bring the compound into both in vivo efficacy studies and finally, 
a clinical setting. 
To ensure that kusunoki inhibition of DENV was not a cell-line or assay-specific 
phenomenon, the effects of kusunoki in a CPE-based anti-dengue assay in monkey 
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kidney (LLC-MK2) cells were explored. This assay was developed based on the CPE of 
DENV-2 infection seen in LLC-MK2 cells and anti-dengue activity of a drug/compound 
is characterized by the rescue of cells from infection-induced cell death (Ichiyama et al., 
2013). The choice of this assay was based on the interest to assess the extent to which 
kusunoki could exert cytoprotective effects, a desirable trait of an anti-DENV drug as 
virus-induced cellular apoptosis is hypothesized to play a role in the pathogenesis of 
DENV infections since local tissue damage or transient homeostatic imbalances could 
trigger additional deleterious events (Marianneau et al., 1998). LLC-MK2 cells, a cell 
line originating from monkeys, were employed with two broad aims. Firstly, the anti-
DENV effects of kusunoki had to be verified to be reproducible in as many DENV-
relevant cell types as possible. With the initial verification in Huh-7.5 cells (human liver 
cells), the study was extended to kidney cells as DENV infection has been known to be 
permissible to a wide multitude of cell types, including liver cells, kidney cells, spleen 
cells, macrophages, monocytes and lymphocytes (Jessie et al., 2004). Moreover, it was 
interesting to be able to reveal if the inhibitory activities of kusunoki was species-
specific, the impetus behind the use of monkey cells in this experiment. 
Kusunoki was found to be similarly non-cytoxtoxic in both LLC-MK2 cells and Huh-
7.5 cells (CC50 in LLC-MK2 cells: 0.183 mg/ml; CC50 in Huh-7.5 cells: 0.202 mg/ml) 
(Figure 3.7 and  
Figure g). This is in line with the knowledge of different kinds of cinnamon being 
safely consumed throughout various cultures for a large gamut of reasons ranging from 
culinary flavouring and as traditional medical remedies. Its  unique position as being 
widely perceived to be safe for consumption would undoubtedly facilitate the clinical 
trial process of any drug or compound derived from the common spice, cinnamon, as it 
is unlikely to fail in toxicity studies. 
Kusunoki’s anti-DENV properties, however, were less apparent in LLC-MK2 cells 
compared to Huh-7.5 cells (EC50 in LLC-MK2 cells: 0.0108 mg/ml and EC50 in Huh-7.5 
cells: 0.000146 mg/ml) (Figure 3.7). This result is acceptable, considering different 
 103 
 
assays of varying sensitivities have been used. Therefore, a general consistent antiviral 
trend (both SIs sigificantly higher than 1) is sufficient for comparison. Furthermore, the 
inhibitory effecrts of kusunoki is much more potent in the human cell line, consistent 
with its future intended use.  
With a SI of 16.8 in LLC-MK2 cells, the ability of kusunoki to inhibit DENV 
replication was established to be independent of the choice of DENV-relevant cell lines 
(liver or kidney cells), species (human or monkey) and assay system used. 
4.8  Inhibitory effect of kusunoki against 4 DENV serotypes 
There are four serologic types of dengue virus, DENV-1 – 4. An ideal property of an 
antiviral inhibitor for dengue would be the ability to protect the host against all the 4 
serotypes. Thus, the capacity of kusunoki to inhibit the 4 serotypes of DENV was 
examined by plaque reduction assay. 
No significant cytotoxic effects were observed with 0 - 100 µg/ml of kusunoki in the 
CPE-based anti-dengue assay (Figure 3.7), indicating that a reduction of plaques was 
solely attributed to the direct anti-DENV action of kusunoki, and not cytotoxicity of the 
compound. Plaques were enumerated after the plaque reduction assay was performed 
(Figure 3.8a) and expressed as a relative percentage to the number of plaques produced 
for incubation with 0.5% DMSO without kusunoki (Figure 3.8b). The concentration 
needed to reduce the number of plaques by 50%, EC50, was then calculated for 
comparison (Figure 3.8c). 
Kusunoki inhibited DENV in the plaque reduction assays in a dose-dependent manner 
(Figure 3.8a – b). This trend was apparent across all 4 DENV serotypes with 
comparable EC50 values (DENV-1: 32.8 µg/ml, DENV-2: 39.0 µg/ml, DENV-3, 16.5 
µg/ml, DENV-4: 30.2 µg/ml, Figure 3.8b - c). 
From this result, DENV-3 seems to display a higher susceptibility to kusunoki with 2-
fold lower EC50 than the other serotypes. If the trend apparent in this set of data is 
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reproducible in vivo, it would be prudent to examine the genetic differences that 
distinguish DENV-3 from the others as this may give an insight into the mechanistic 
action of kusunoki for further understanding and exploitation for the drug discovery 
process against DENV. 
The broad-spectrum inhibition of kusunoki against all four DENV serotypes is an 
extremely important trait of an anti-DENV drug to be used in a global setting. Although 
the dominant DENV serotype in Singapore has been serotype 2 since 2007, it is 
important to comprehend that the dynamics of the disease remains in constant flux. For 
example, within a small local community like Singapore, the proportions of DENV-1 
and DENV-3 infections have increased from 5% and 12% in September 2012 to 25% 
and 20% in February 2013 respectively (NEA, 2013). In a global context, although 
DENV serotypes used to be limited by geographical boundaries 30 years ago, disease 
transmission of all four serotypes have since been found circulating in tropical and 
subtropical regions of the world, including Asia, Africa and the Americas, a significant 
portion of the present globalized world (Guzman et al., 2010). Coupled to incidences of 
heterologous DENV infections, it is imperative for the development of a drug which can 
be used in the universal treatment of DENV regardless of its serotype in a rapid manner, 
without having to additionally consider the DENV serological differences in infected 
patients. 
4.9  Mechanistic inhibitory action of kusunoki 
To give mechanistic insights into the anti-DENV action of kusunoki, a time of addition 
assay was first performed. This assay broadly dichotomizes inhibitors by distinguishing 
their mode of action, differentiating attachment/entry inhibitors from intracellular 
inhibitors that work against any other step in the rest of the viral replication cycle, by 
adding the inhibitor in question at different time points before and after viral inoculation 
and examining the extent of viral inhibition. 
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Supporting its role as a RdRp inhibitor discovered by the in vitro RNA polymerization 
assay (Figure 3.4b and Figure 3.5b), viral inhibition was apparent in early stages of the 
infection (Figure 3.9a, >1 h post infection), at time points consistent with steps in the 
viral replication cycle which occur intracellularly after entry and internalization of the 
viral particle (Wang et al., 2011b).  
Next, to further support the hypothesis that kusunoki is a possible RdRp inhibitor, a 
DENV subgenomic replicon encoding the NS proteins was used. At a low concentration 
of 40 µg/ml, kusunoki was sufficient to reduce replicon activity by 50% (Figure 3.9b), 
consistent with its ability to inhibit in vitro RdRp activity (Figure 3.4b). This possibility 
is reminiscent of previous reports that describe the effective inhibition of PAs isolated 
from blueberry leaves on HCV subgenomic replicon expression, which is a flavivirus 
closely related to DENV (Takeshita et al., 2009). 
Surprisingly, a higher degree of viral inhibition was evident when kusunoki was added 
at even earlier time points (-1.5 to 1 h) post infection in the time of addition assay 
(Figure 3.9a). The inhibitory profile of kusunoki at these time points was found to be 
similar to that of heparin, a known DENV entry inhibitor (Figure 3.9a). This suggests 
that kusunoki can inhibit attachment/entry of DENV, in addition to inhibiting 
intracellular viral RNA replication. 
In an attempt to clarify if kusunoki inhibits DENV at either the viral attachment or 
internalization step, a binding assay was performed. This assay is based on early 
findings that distinguished both processes. While viral attachment is a temperature-
independent process which occurs at both 4 and 37°C, viral internalization can only 
proceed at 37°C (Salas-Benito and del Angel, 1997). 
High levels of viral inhibition were observed at 4°C, while a comparable 100% 
inhibition was achieved at 37°C (Figure 3.9c). This suggests that kusunoki possibly 
inhibits DENV attachment to host cells. The ability of PAs to prevent viral attachment 
to host cells has been exemplified in previous studies and may occur through two broad 
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levels. In the case of HIV-1, PAs from grape seeds have been shown to be able to 
directly downregulate the expression of the viral entry co-receptors, CCR2b, CCR3 and 
CCR5, although the mechanism is currently unknown (Nair et al., 2002). On the other 
hand, PAs have been observed to interact with the viral envelope proteins 
extracellularly, causing their oligodimerization and thereby blocking their attachment to 
receptors to host cells (Gescher et al., 2011a). As kusunoki is able to exert inhibition of 
RNA replication at an intracellular level, it may be postulated that the transport of 
kusunoki into the cell occurs adequately. The significant blocking of viral attachment 
could be possibly due to a combination of multiple modes of action such as those 
aforementioned at both intracellular and extracellular levels. 
Two forms of evidences may add to the credibility of the proposed multifaceted 
inhibitory roles of kusunoki in this study.  
Firstly, the phenomenon of the multiple roles of PAs has been extensively reported. For 
example, the PA epigallocatechin gallate (EGCG), most commonly found in green tea, 
has been found to inhibit multiple viral enzymes involved in stages of the HIV-1 
replication cycle including reverse transcriptase, integrase and protease (Jiang et al., 
2010; Yamaguchi et al., 2002). In addition, EGCG has also been implicated in the 
inhibition of host factors such as nitric oxide synthase, NF- B and casein kinase 2 to 
suppress HIV-1 infection (Haneda et al., 2000; Melgarejo et al., 2010; Yamaguchi et al., 
2002). As DENV NS5 have also been shown to possess a casein kinase 2 site that has 
been implicated in the nuclear targeting of NS5, probably by means of a cytoplasmic 
retention mechanism, EGCG could also be involved in host-mediated suppression of the 
virus.  It is interesting to note that epigallocatechin has been reported to be found in 
extracts isolated from cinnamon tree bark, bringing about the possibility of its esterified 
counterpart being present as well (Mateos-Martin et al., 2012).  
Secondly, kusunoki, the PA oligomer fraction of the extract contains a myriad of PAs. If 
a single PA such as EGCG has the ability to have multiple modes of inhibitory action on 
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HIV-1, it would be plausible for either a single or multiple PAs in this extract to exhibit 
the numerous inhibitory effects on DENV shown in this study.  
Thus, kusunoki is able to inhibit DENV replication at both the viral attachment, as well 
as the NS5-mediated RNA replication steps.  
In this study, hits were obtained through the screening of libraries of FDA-approved 
drugs and natural compounds in an in vitro NS5 RdRp assay. These compounds may be 
a distance away from ideal drugs for administration under clinical settings given their 
selectivity indices. Nevertheless, this may be attributed to the screening of a mere 648 
drugs/compounds. Presently, the in vitro NS5 RdRp assay resulted in an overall hit rate 
of 1.2% using a conservative criterion of 50%. This is in comparison to other primary 
HTS assays utilizing random compound libraries to identify RdRp inhibitors that 
typically use a more liberal range of 25 - 50% RdRp activity inhibition cut-off to yield 
lower hit rates ranging from 0.001% to 0.7% (Niyomrattanakit et al., 2011; 
Niyomrattanakit et al., 2010; Wang et al., 2011a). Subsequently, 0.77% of the overall 
drugs/compounds were validated to have an anti-DENV effect. Thus, more ideal 
antiviral drugs may be uncovered if the present screening system is used with larger 
drug/compound libraries. This attempt can also be strengthened and made more efficient 




Chapter 5. Future Directions 
5.1  Extension of screening libraries 
The overall significantly higher hit rate in this study suggests that the approach taken by 
the study in terms of choice of screening libraries comprising of safer alternatives in 
comparison to other random compound libraries could be a more efficient way to 
identify RdRp inhibitors. With this result, the study should be extended to a bigger 
library of FDA-approved drugs, health supplements that have been approved by relevant 
authorities and traditional medications that mostly comprise of natural compounds. The 
choice of these as screening material would mostly translate to non-cytotoxic hits, and 
would greatly expedite the clinical trial process. 
5.2  Determination of active antiviral components in kusunoki PA extract 
The kusunoki extract used in the study was a polyphenol-enriched extract rich in 
oligomeric (high molecular weight) PAs. It would be interesting to compare the 
different molecular weight fractions of kusunoki (low, medium, high) to see differences 
in their DENV inhibitory profile to explore if the extent of oligomerization of the PAs 
affects their antiviral effect.  
In particular, it would be essential to further resolve and identify all the oligomeric PAs 
present in the extract isolated from kusunoki that was used in this study. These should 
then be subjected to the same tests to elucidate their potential inhibitory mechanisms in 
order to find out how each PA contributes to the anti-DENV effect shown by kusunoki. 
In addition, as the isolation process of the various PAs may not be fully efficient, there 
is a possibility of contaminants being present in trace amounts. These include other 
compounds that may be found in cinnamon bark such as camphor, safrole, dipentenes, 
cineole, borneole, camphene, terpeneol and linalool (Daniel, 2005). As compounds such 
as camphor have also been shown to have antiviral activity (Chen et al., 2013), the 
verified PAs should then be ideally obtained from a different source (commercially or 
synthesized) to decrease chances of contaminants and ensure reproducibility in results.  
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5.3  Verification of RdRp inhibition 
To verify if the drugs or compounds indeed inhibit RdRp, a multidimensional approach 
should be taken. Firstly, in silico screening and docking experiments can be utilized to 
reveal possible binding sites of the PA on NS5. Simultaneously, the generation of viral 
strains resistant to the drug or compounds should be attempted in cell culture 
experiments. Any escape mutations that is traced back to the RdRp domain could 
suggest that the drug or compound in question is an inhibitor of viral RNA polymerase. 
In addition, any additional mutations in other regions could imply interactions with 
RdRp domain of NS5. 
Results from both in silico and resistant virus experiments should ideally corroborate 
with each other and reinforce our understanding of the drug or compound. A final step 
would then be to generate a drug- or compound-resistant protein mutant by site-directed 
mutagenesis and perform both the in vitro NS5 RdRp assay and cell culture experiments 
to validate these results. 
To further substantiate these sets of data, the binding affinity of DENV NS5 protein and 
the drug or compound may be measured by surface plasmon resonance technology. 
5.4  Determination of antiviral effects against other flaviviruses 
A desirable property of an anti-DENV drug would be the broad-spectrum inhibition 
against a wide range of other flaviviruses. Out of 44 sets of highly conserved DENV 
sequences across all four serotypes, 27 were found in as many as 64 other viruses in the 
family Flaviviridae (representatives that are human pathogens include WNV, St. Louis 
encephalitis virus, JEV and YFV) and 13 of these represented sequences in NS5, the 
viral target of this study. This suggests that an inhibitor targeting NS5 could have a 
higher possibility of being a broad-spectrum antiviral. 
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Drugs and compounds that are found to be inhibitors of NS5 RdRp activity should 
therefore be screened against other flaviviruses as they would also aid in filling the void 
caused by the lack of antivirals for flavivirus infections. 
5.5  Combination treatment 
DENV NS5 RdRp presents as an attractive drug target because of its position as a viral-
specific protein which plays a vital role in viral RNA replication. In addition, it is also 
highly conserved across all four DENV serotypes and many flaviviruses. Additionally, 
this protein also has a vital role in viral RNA replication. Even so, the emergence of 
drug resistance remains a constant problem, as seen in anti-HIV and HCV therapy (Xie 
et al., 2011). 
A strategy to minimize drug resistant viral strains has been successfully employed in 
antiretroviral therapy for patients afflicted with HIV. This method utilizes a 
combination of two to three antiviral drugs that have different inhibitory mechanisms 
such as two nucleoside-analogue reverse transcriptase and a protease inhibitor 
(Imamichi, 2004). For example, in the case of DENV, protease or entry inhibitors may 
be used in combination with RdRp inhibitors. Alternatively, inhibitors with novel or 
unconventional mechanisms may be targeted. This includes viral proteins without 
enzymatic activity, and has been shown for NS5A in HCV (Gao et al., 2010). 
Apart from preventing viral resistance, the use of combination treatment could also 




Chapter 6. Conclusion 
6.1  Summary of study findings 
With the increasing recognition of RdRp activity of NS5 as an attractive drug target, 
this protein was chosen as a target for anti-DENV drug screening. The synthesis of high 
quality DENV-2 NS5 as well as its RdRp domain mutant by utilizing the wheat germ 
cell-free protein synthesis system was accomplished in this study. This was an attempt 
to present these proteins as an alternative to other present protein synthesis methods that 
balances cost, efficiency and physiological relevance.  
These recombinant NS5 proteins were then successfully applied in the development of a 
fluorescence-based in vitro RdRp assay which was then used in the identification of 
inhibitors against DENV NS5 by screening libraries of FDA-approved drugs and natural 
compounds. Compared to other similar studies, this study achieved a significantly 
higher hit rate of 1.2% using a conservative cut off criterion, suggesting that the choice 
to screen drugs and compounds, a safer (i.e. less cytotoxic) alternative to newly 
synthesized compounds could be a more efficient way to identify RdRp inhibitors. 
Eight drugs/compounds were shortlisted by the in vitro screening, and their anti-DENV 
potential was further evaluated in a cell-based DENV infection system by exploring 
their cytotoxicity and capacity to reduce viral titers. Of these, five (itraconazole, 
entacapone, butoconazole nitrate, pinacidil and kusunoki) showed an SI of higher than 
1, showing that 62.5% of the shortlisted drugs and compounds demonstrated anti-
DENV activity in cultured cells. As kusunoki (a polyphenol-enriched extract rich in 
oligomeric PAs derived from the bark of the Japanese cinnamon tree) had reflected the 
highest SI, this was chosen for further downstream validation experiments. 
The antiviral effect of kusunoki was demonstrated to be reproducible in a cell-type and 
assay-independent manner. In addition, its broad-spectrum inhibition against all four 
DENV serotypes was shown. Insights into the mechanistic action of kusunoki suggests 
that it not only serves as a RdRp inhibitor, but could also further inhibits DENV by 
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preventing viral attachment to host cells prior to entry. Kusunoki therefore holds great 
potential as an anti-DENV compound for further development into an antiviral drug. 
The hits from this study may be a distance away from ideal drugs for administration 
under clinical settings given their selectivity indices. Nevertheless, this may be 
attributed to the screening of a mere 648 drugs/compounds. With larger drug/compound 
libraries used in the present screening system, more ideal antiviral drugs may be 
uncovered. This attempt can also be strengthened and made more efficient with the 
combination of in silico prescreening. 
6.2  Future perspectives 
A further understanding of the pathogenesis of DENV infections could possibly lead to 
the identification of novel drug targets. 
In parallel, it is presently also vital to build on existing knowledge to fully exploit 
known viral targets. This may be in the form of uncovering the detailed mechanisms and 
molecular clockwork of these viral proteins, as well as solving their crystal structure to 
aid rational drug design. It is also essential to systemically ensure that pharmaceutical 
R&D efforts to date are maximized by repositioning drugs to various other indications 
whenever possible. 
While the discovery of new antiviral drugs against DENV is of paramount importance, 
the future of anti-DENV efforts could perhaps lie in the combination of such 
compounds to bring about synergistic antiviral effects, as well as to ensure the longevity 
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